

Steven J. Shoptaw, Ph.D.  
Curriculum Vitae

**PERSONAL HISTORY:**

Center for Behavioral and Addiction Medicine  
UCLA Department of Family Medicine  
10880 Wilshire Blvd., Suite 1800  
Los Angeles, California 90024  
Tel: (310) 794-6206  
Fax: (310) 794-6097  
E-mail: sshoptaw@mednet.ucla.edu

**EDUCATION:**

B.A. in Psychology, University of California, Los Angeles Cum Laude, Dean's Honor List, Honor's College	1980 – 1982
M.A. in Psychology, University of California, Los Angeles	1985
Ph.D. in Psychology, University of California, Los Angeles Major – Clinical, Minors - Psychometrics and Developmental Dissertation nominated for Gingerelli Award in Psychology	1985 – 1990
Postdoctoral Scholar, Psychophysiology, UCLA, NPI/VA Sepulveda Medical Center	1990 – 1991

**LICENSURE:**

California Psychology License Number 13300	1993 – 2022
--	-------------

**BOARD CERTIFICATION:**

**PROFESSIONAL EXPERIENCE:**

Professor, Department of Psychiatry & Behavioral Sciences, UCLA	2005 – Present
Professor, Department of Family Medicine, UCLA	2005 – Present
Professor (Hon), Department of Psychiatry and Mental Health, UCT	2012 - Present
Director and Attending Psychologist, Behavioral Medicine Program, Family Health Center, UCLA	2010 – 2016
Vice Chair of Research, Department of Family Medicine, UCLA	2014 – Present

Vice Chair of Academic Affairs, Department of Family Medicine, UCLA	2008 – 2013
Director, UCLA Vine Street Clinic, UCLA	2004 – Present
Research Psychologist, Psychiatry, UCLA	2003 – 2005
Executive Director, Safe House Residence, North Hollywood, CA	1996 – 2015

**PROFESSIONAL ACTIVITIES:****Committee Service**

Ad hoc Reviewer to National Institute Health Study Section	1993 – 2006
Member, NIDA-L Pharmacotherapy Study Section	2006 – 2009
Program Co-Director, Sociocultural Issues in HIV Prevention, UCLA AIDS Institute, UCLA	2005 – 2019
Executive Director, UCLA Center for Behavioral and Addiction Medicine	2011 – Present
Member, HIV Prevention Trials Network Executive Committee	2014 – 2020
Executive Committee Liaison, HIV Prevention Trials Network Substance Use Scientific Committee	2014 – Present
Standing Member, Interventions to Prevent and Treat Addictions Study Section (IPTA): Risk, Prevention and Health Behavioral Integrated Review Group	2015 – 2016
Chair, Interventions to Prevent and Treat Addictions Study Section (IPTA): Risk, Prevention and Health Behavioral Integrated Review Group	2016 – 2015
NIDA Representative, AIDS Clinical Trials Group, ACTG 5359	2016 – Present
Member, RPIA-N (Risk, Prevention and Intervention for Addictions) Study Section for NIH	2009 – 2011
Co-Chair, HIV Prevention Trials Network Substance Use Scientific Committee	2011 – 2013
Co-Director, Combination Prevention Core, Center for HIV Identification, Prevention & Treatment Services, UCLA	2000 – 2018
UCLA Center for AIDS Research, Biobehavioral Epidemiology & Substance Use Research (BESU) Program Section	2016 – 2019
Member, Implementation Activities and Adherence Working Group of the Antiretroviral Therapy Strategies Transformative Science Group.	2018 – Present
Participant, NIDA ARP Strategic Planning Workshop, HIV/AIDS and Substance Use,	2018

Misuse, Addiction: Clinical, Translational, and Epidemiology Research. November 14.	
Reviewer. NIH Support for Conferences and Scientific Meetings (R13) Applications. November 14-16.	2018
Moderator. HPTN Annual Meeting Plenary Session. May 18.	2018
Reviewer, Lancet Series on Drugs. Joint Peer Reviewers', Authors', and Editors', Meeting. October 15.	2018
Reviewer, South American Program in HIV Prevention Research (SAPHIR)	2017 – Present
Editor & Reviewer, UCLA "Substance Abuse in the Workplace" Brochure	2019
Primary Reviewer, HPTN 087, A multicenter, randomized, partially blinded phase 1 clinical trial to evaluate the safety and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected adults.	2017
Primary Reviewer, HPTN 089, A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adult participants	2019
Reviewer, Behavioral Working Group for the MACS/WIHS	2016 – Present
Reviewer, University of Washington CFAR Supplements	2018
Reviewer, City University of New York CFAR Supplements	2018
Reviewer, UC Cannabis and Hemp Research Center Application	2018
Reviewer, South African Medical Research Council Proposal for Collaborative Centre for Evidence-Based Treatment of Mental Disorders	2019
Independent Career Reviewer, University of Cape Town Academic Promotions Committee	2017
Member, UCSF Center for AIDS Prevention Studies Scientific Advisory Board	2016 - Present
Advisory Group Member, CTN 0114, Drug repurposing for cocaine use disorder (CUD) using a combined strategy of artificial intelligence (AI)-based prediction and retrospective clinical corroboration”	2020 - Present
<b>Community Service</b>	
Grant Reviewer, Los Angeles County Division of HIV and STD Programs	2015 – 2017
Volunteer Executive Director, Safe House	1989 – 2015

## **Professional Associations**

## **Scholarly Societies**

## **Editorial Services**

Reviewer, AIDS Care	2005
Assistant Editor, ADDICTION	2005 – 2016
Assistant Editor, Journal of Addictive Diseases	2005 – Present
Reviewer, American Journal of Public Health	2007
Reviewer, Journal of Applied Behavioral Sciences	2007
Reviewer, Journal of Applied Behavioral Analysis	2007
Reviewer, BioMed Central	2008
Reviewer, Psychological Bulletin	2008
Reviewer, AIDS and Behavior	2009
Reviewer, Journal of Urban Health	2009
Reviewer, Experimental Clinical Psychopharmacology	2009
Reviewer, Psychology of Addictive Behaviors	2009
Reviewer, Culture, Health and Sexuality	2009
Reviewer, Journal of STIs	2009
Reviewer, Prevention Science	2009
Reviewer, United Kingdom Medical Research Council	2009
Reviewer, American Journal of Drug and Alcohol Abuse	2009
Reviewer, Journal of the National Medical Association	2009
Reviewer, Clinical Infectious Disease	2009
Reviewer, Journal of Substance Abuse Treatment	2009 – Present
Reviewer, Journal of General Internal Medicine	2009

Reviewer, Journal of Epidemiology	2009
Reviewer, Annals of Behavioral Medicine	2009
Reviewer, Journal of Addictive Medicine	2009
Reviewer, American Recovery and Reinvestment Act Grant Reviews	2009 – 2010
Deputy Editor, Drug & Alcohol Review	2009 – 2016
Reviewer, Sexual Transmitted Infections	2011
Reviewer, ADDICTION	2011 – Present
Reviewer, Drug and Alcohol Dependence	2011 – Present
Reviewer, Drug and Alcohol Review	2011 – Present
Reviewer, Journal of Addictive Diseases	2011 – Present
Reviewer, BMC Public Health	2011 – Present
Reviewer, Journal of Urban Health	2011 – Present
Reviewer, Experimental and Clinical Psychopharmacology	2011 – Present
Reviewer, AIDS & Behavior	2011 – Present
Reviewer, Psychology of Addictive Behaviors	2011 – Present
Reviewer, American Journal of Drug and Alcohol Abuse	2011 – Present
Reviewer, International Journal of STD and AIDS	2012
Reviewer, Biological Psychiatry	2012
Reviewer, AIDS Care	2012 – 2013
Reviewer, PLOS One	2012 – 2013
Reviewer, Health Affairs	2013
Reviewer, Clinical Infectious Diseases	2013
Reviewer, Journal of Clinical Psychiatry	2013
Reviewer, Alcohol and Alcoholism	2013

Reviewer, Journal of the Acquired Immunodeficiency Syndrome	2013
Associate Editor, Drug and Alcohol Dependence	2016 – Present
Editorial Board Member, AIDS Care	2018 – Present
Reviewer, International Journal of Drug Policy	2017
Reviewer, Forensic Science Research	2016
Reviewer, BMJ Open	2016
Reviewer, Substance Use & Misuse	2016
Reviewer, Neuropsychopharmacology	2017 – Present
Reviewer, Epidemiological Reviews	2017 – Present
Reviewer, Contemporary Clinical Trials	2017
Reviewer, Archives of Sexual Behavior	2018
Reviewer, Journal of General Internal Medicine	2018
Reviewer, Lancet HIV	2018 – Present
Reviewer, American Journal of Psychiatry	2018 – Present
Reviewer, American Journal of Addiction	2019
Reviewer, American Academy of Thoracic and Cardiovascular Surgery	2019
Reviewer, Journal of Sex Research	2019
Reviewer, Lancet Psychiatry	2019

**Community Service to University**

Member, Data, Safety and Monitoring Board – Addiction Medicine, UCLA	2005 – Present
Director, UCLA Center for Health Promotion & Disease Prevention	2006 – Present
Member, UCLA School of Medicine, Quality Assurance Committee	2007 – 2009
Member, Department of Family Medicine Committee for Academic Promotion (FM-CAP), UCLA	2008 – Present

Member, Executive Council Committee, Department of Family Medicine, UCLA	2008 – Present
Reviewer, CFAR Seed Grant Program, UCLA AIDS Institute, UCLA	2009 – 2019
Member, David Geffen School of Medicine Community Engagement Strategy Design Team, UCLA	2010 – 2011
Reviewer, KL2 Program, Clinical and Translational Science Institute, UCLA	2012 – Present
Reviewer, Clinical and Translational Research Scientific Advisory Committee, UCLA	2013 – Present
Member, Clinical and Translational Science Institute Educational Core, UCLA	2013 – 2018
Reviewer, Clinical and Translational Science Institute Pilot Funds, UCLA	2013 – Present
Chair, Secondary Review Committee for 8-Year Limit Action, UCLA	2015 – 2015
Member, 5-Year Chair Review Committee, UCLA	2015 – 2016
Interviewer, Residency Admissions, Department of Infectious Disease, UCLA	2016 – Present
Interviewer, Residency Admissions, Department of Family Medicine, UCLA	2005 – Present
Interviewer, Residency Admissions, Department of Psychiatry and Biobehavioral Sciences, UCLA	2015 – Present
Interviewer, Graduate Admissions, Department of Psychology, UCLA	2019 – Present
Reviewer, South American Program in HIV Prevention Research (SAPHIR) Fellow Research Grants, UCLA	2018 – Present
Interviewer, South American Program in HIV Prevention Research (SAPHIR) Fellowship Applicants, UCLA	2018 – Present
<b>Community Action</b>	
Matrix Institute, Board Member	1996 – 2003
Chair, HIV Workgroup, Clinical Trials Network, National Institute on Drug Abuse	1999 – 2002
Board Member, City of Los Angeles Mayor’s Commission on HIV/AIDS	2000 – 2001
Mission City Community Network, Board Member	2000 – 2001
Methamphetamine Task Force, Los Angeles County	2007 – 2011
Board Member, AIDS Project Los Angeles	2011 – 2016

Ambassador, AIDS Project Los Angeles	2016 – Present
Board Member, MusiCares	2020 – Present

**Consulting Activities**

Community Agency Consultant, Visiting Nurses' Association, Pasadena, CA; Garvey School District, Rosemead, CA. Met with agency management and created description and time plan for providing psychological services to agency personnel.	Sept 1986 – Aug 1987
Statistics Consultant. Provided consultation and statistical services to UCLA, USC, Fuller, and CSPP-LA doctoral students in psychology.	Sept 1987 – 1994
Statistical Consultant, Glen Roberts, Roberts' Apperception Test for Children. Developed strategy for re-norming test and devising more sensitive subscales. Provided general consultation services to the Glen Roberts Child Study Clinic.	Jan 1989 – Oct 1991
Communication Skills Workshop, UCLA-California Self-Help Center. Conducted 4-hour training in communication skills for phone referral specialists using experiential and mini-lecture format.	March, 1990
Technical Consultant, United Nations Office of Drugs and Crime. Lead development of technical guidelines for HIV prevention, treatment and care among cocaine and stimulant drug users.	Sept 2011 – Aug 2016
Prevention Panel Member, Biobehavioral HIV Prevention Guidelines, International Antiviral Society-USA (IAS-USA). Collaborated to edit and write guidelines for HIV prevention to enhance educational and informational programs for practitioners actively involved in medical care.	Jan 2013 – Jan 2015
Research Advisory Committee Member, Robert Wood Johnson Foundation New Clinical Scholars Program Design Project	Oct 2014
Professional Consultation Services, NFL	2015 – Present
Professional Consultation Services, UCLA Athletics Department	2015 – Present

**HONORS AND SPECIAL AWARDS:**

The Daniel Mendelsohn Young Investigator Award, Friends Research Institute	1996
The Community Prevention Council & LGBT Tobacco Council Consortia	2003
13th Annual Spirit of Hope Award, Being Alive	2005



**RESEARCH GRANTS & FELLOWSHIPS:****COMPLETED:**

- P.I., A Structured Treatment Manual for HIV+ Substance Abusers (1R43 DA08786, \$60,000) 1993
- Co-P.I., Behavioral/Cognitive Behavioral Trial for Cocaine Abuse (1R01 DA09419, \$2.5 million) 1994 – 1999  
*Purpose: This study is to evaluate two promising approaches, relapse prevention (RP) and contingency management (CM), for the treatment of cocaine abuse with two populations.*
- P.I., A Structured Treatment Manual for HIV+ Substance Abusers (1R44 DA08786, \$600,000) 1995 – 1997  
 1996 – 1999
- P.I., Contingency Management - Tobacco Smoking in Opiate Addicts (1R01 DA09992, \$750,000)  
*Purpose: The purpose of this study was to determine whether contingency management was effective in helping opiate users to quit smoking.*
- P.I., Behavior Therapy for Gay Male Methamphetamine Users (1R01 DA11031, \$1.6 million) 1997 – 2001  
*Purpose: The major goal of this project is to complete a 140-subject trial of 0.5 mg/week cabergoline compared to placebo (70 subjects per group) over a one-year period. Trial results will be used to determine whether to proceed with a multi-site study of cabergoline, with the goal of filing a new drug application for cabergoline with the FDA for the indication of cocaine pharmacotherapy.*
- P.I., Safe House: Comprehensive Residential and Client Services for Multidiagnosed Persons. Housing Opportunities for Persons with AIDS, City of Los Angeles, HUD (\$2.6 million) 1997 – 2015  
*Purpose: The mission of Safe House is to provide low cost, safe and decent housing to a community of persons who are frequently homeless: those living with HIV/AIDS who also have a mental illness and/or chemical dependency using a philosophy of high tolerance.*
- P.I., Behavioral Therapies for Gay Male Stimulant Abusers, CSAT (1KD1 12043, \$1.2 million) 1999 – 2002  
*Purpose: The major goal of this project is to compare efficacy of culturally specific behavioral treatments for substance-related problems. In addition, we intend to develop manuals as a resource for those who work with gay/bisexual stimulant dependent men and ascertain methods for using substance abuse treatment and HIV prevention materials to educate this high-risk population.*
- Co-Investigator, Clinical Trials Network – UCLA Research Node (U01 DA013045, \$2.2 million) 1999 – 2015  
*Purpose: The major goal of this project is to conduct and participate in behavioral, pharmacological and combined behavioral and pharmacological treatment trials for drug abuse dependence and to conduct research on treatment practices within and across the NIDA Clinical Trials Network Nodes.*  
 PI: Walter Ling, MD

- P.I., Phase 2, Double-Blind, Placebo-Controlled Trial of Two Doses of Cabergoline for Treatment of Cocaine Dependence (N01 DA-0-8804, \$1.7 million) 2000 – 2003  
*Purpose: The major goal of this project is to complete a 140-subject trial of 0.5 mg/week cabergoline compared to placebo (70 subjects per group) over a one year period. Trial results will be used to determine whether to proceed with a multi-site study of cabergoline, with the goal of filing a new drug application for cabergoline with the FDA for the indication of cocaine pharmacotherapy.*
- P.I., Medication Development Unit for Stimulant Medications (1P50 DA 12755, \$4.8 million) 2000 – 2004  
*Purpose: The major goals of this project are to implement an articulated clinical program of stimulant pharmacotherapy trials. These studies are oriented exclusively to treatment of cocaine and methamphetamine dependence.*
- Co-P.I., Intervention Core, UCLA Center for HIV Identification, Prevention, and Treatment Services (Center P.I., Rotheram-Borus, 5P30 MH058107, \$1.0 million) 2002 – 2011  
*Purpose: The Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) is a collaboration of researchers from UCLA, Charles Drew University of Medicine and Science, Friends Research Institute, and RAND working with the broader Los Angeles community toward a common goal: to enhance the collective understanding of HIV research and to promote early detection, effective prevention, and treatment programs for HIV.*
- P.I., Phase 2, Double-Blind, Placebo-Controlled Trial of Baclofen for Cocaine Dependence (NIDA Cooperative Studies Program - CSP-1021) 2003 – 2005  
*Purpose: The purpose of this study was to test the effectiveness of the medication, Baclofen, to treat cocaine dependence.*
- P.I., Evaluation Technical Assistance for Coordinated Prevention Networks (CDC; H700024; \$1.5 million) 2003 – 2006  
*Purpose: This is technical assistance contract to assist four community based organizations in building prevention networks for HIV/STD/TB/SA by developing standardized client tracking forms and network evaluation forms.*
- P.I., HIV/STD Risk Behaviors in Methamphetamine User Networks (1U01 DA 17394, \$5.1 million) 2003 – 2009  
*Purpose: This is a multidisciplinary effort to examine the diffusion of HIV and sexually transmitted diseases (STDs) through drug using sexual networks in Los Angeles County and to identify the contributions of individual-level factors, partner-level factors, and environmental factors that promote the spread of these diseases.*
- Co-P.I., Methamphetamine Abuse Treatment is HIV Prevention (UARP MU 04-LA-705, \$750,000) 2004 – 2007  
*Purpose: This project will evaluate the effects of a drug counseling treatment coupled with a behavioral treatment that gives rewards to participants for providing urine samples that show no recent use of methamphetamine.*
- P.I., UCLA Medication Development Unit for Stimulant Abuse (1P50 DA18185, \$5.7 million) 2004 – 2010

million)

*Purpose: The major goal of this project is to develop pharmacological treatments for stimulant abuse through comprehensive and efficient methodologies applied by a multidisciplinary team. This project continues and expands upon the work of the above-referenced P50 DA12755 which recently expired.*

Co-P.I., Mirtazapine to Reduce Methamphetamine Use Among MSM with High-Risk HIV Behaviors (R01 DA021090 \$40,718) 2006 – 2009

*Purpose: This is a randomized, double-blind, placebo- controlled trial to determine the efficacy of mirtazapine in reducing sexual risk behavior among high-risk men who have sex with men (MSM) with a number of biological and behavioral outcomes, including methamphetamine use, sexual risk behavior, and adherence to therapy.*

PI: Grant Colfax

Co-P.I., Double-blind, Placebo-Controlled Trial of PROMETA for Methamphetamine Dependence (Hythiam, Inc. \$2.8 million) 2007 – 2008

*Purpose: The goal of this research study was to test the efficacy of a pharmaceutical intervention in combination with behavioral therapy and two short hospital stays.*

PI: Walter Ling

P.I., Pilot Study of Pain, Substance Use, and HIV Risk Behaviors (CHRP-AIDS Research \$30,000) 2007 – 2008

P.I., Pre-Exposure Prophylaxis (PrEP) and Non-occupational Post Exposure Prophylaxis (nPEP) for HIV prevention in Los Angeles (City of Los Angeles contract C112361, \$36,000) 2007 – 2009

*Purpose: The goal of this project is to gather formative information on the feasibility and acceptability of PrEP for HIV prevention in Los Angeles.*

Co-Investigator, Long-term Health Effects of Methamphetamine Use in the MACS (U10 DA13045, \$149,395) 2007 – 2010

*Purpose: The goal of this project is to determine the long-term health effects of methamphetamine use within an existing cohort of men who have sex with men (MSM) participating in the Multicenter Cohort Study (MACS). More specifically, this proposal focuses on the stimulant abuse effects on health issues that occur at the intersection of mental health, drug abuse and HIV infection.*

PI: Roger Detels

Co-Investigator, Transmission Behavior in Partnerships of Newly HIV Infected Southern Californians (R01 DA022116, \$525,842) 2007 – 2009

*Purpose: The goal of this project is to look at the role of recent infection on the transmission of HIV among gay men in the US.*

PI: Pamina Gorbach

P.I., Los Angeles Coordinated HIV Needs Assessment (L.A. County Q40065 Service Contract, \$155,033) 2007 – 2010

*Purpose: to provide data analysis and training services required by the Commission to fulfill its annual needs assessment, priority- and allocation-setting and comprehensive care*

planning processes.

P.I., Los Angeles County Methamphetamine Prevention Initiative (L.A. County Q42908 Service Contract, \$60,000) 2008 – 2010

*Purpose: Proposal for development and implementation of methamphetamine treatment and prevention training for county-funded agencies.*

Co-Investigator/Mentor, Pharmacogenomics and Medication Development for Methamphetamine Dependence (K23 DA023558, \$885,190) 2008 – 2013

*Purpose: The goal of this mentored, patient-oriented research career development award is to provide Dr. Heinzerling with the training and experience needed to become an independent clinical investigator in the area of pharmacogenomic approaches to medication development for substance abuse, with an emphasis on MA use disorders.*

PI: Keith Heinzerling

Co-Investigator, Pilot Trial of Bupropion vs. Placebo for MA Abuse in Adolescents (R21 DA026513, \$285,680) 2009 – 2011

*Purpose: The goal of this pilot study is to assess the safety, tolerability and acceptability of Bupropion among adolescents with methamphetamine abuse and to optimize clinical trial methods for use with this population.*

PI: Keith Heinzerling

Site P.I., Feasibility of a community-level, multi-component intervention for Black MSM in preparation for a Phase IIB community-level randomized trial to test the efficacy of the intervention in reducing HIV incidence among Black MSM, HIV Prevention Trials Network—Protocol 061 (5 U01 AI069424, \$2,951,690) 2009 – 2012

*Purpose: The goal of this project is to determine the feasibility and acceptability of a multi-faceted intervention among Black MSM to prepare for a community-level randomized trial to test the efficacy of the intervention in reducing HIV incidence.*

Co-Investigator, HBV Prevention for Homeless At-Risk for HBV/HCV/HIV (R01 DA016147, \$433,571) 2009 – 2014

*Purpose: The goal of this program is to assist young homeless stimulant -using gay and bisexual homeless men to complete the HAV/HBV vaccine and in reducing drug and sexual activity.*

PI: Adeline Nyamathi

P.I., UCLA Training Program on Addiction Medicine in Primary Care (T32 DA026400-01, \$672,320) 2009 – 2014

*Purpose: The goal of this training program is to provide physician and behavioral trainees with the research, academic training and mentored professional development to transition into independently funded clinical researchers in the emerging area of research on the topic of addiction medicine in primary care.*

- P.I., Phase I Safety Interaction Trial of Ibudilast with Methamphetamine (R01 DA029804, \$1,059,909) 2010 – 2013  
*Purpose: The proposed study is a Phase I clinical trial that will utilize a randomized double-blind, placebo-controlled within-subject crossover design to determine safety and tolerability and subjective and reinforcing effects of MA in 12 non-treatment seeking MA-dependent volunteers treated with Ibudilast and placebo.*
- Co-Investigator, Randomized Trial of Ibudilast for Methamphetamine Dependence (R01 DA035054, \$3,428,943) 2010-2018  
*Purpose: The goal of this phase 2, randomized trial is to determine whether Ibudilast reduces methamphetamine (MA) use more than placebo among MA dependent participants and to determine whether Ibudilast results in longer treatment retention than placebo among MA dependent participants.*  
 PI: Keith Heinzerling
- Co-Investigator, Pharmacogenetics of Naltrexone for Methamphetamine Use Disorders (R21 DA029831, \$150,000) 2011 – 2013  
*Purpose: This study seeks to characterize the biobehavioral effects of naltrexone for methamphetamine use disorders and to extend its pharmacogenetics.*  
 PI: Lara Ray
- Co-Investigator, Enhanced Comprehensive HIV Prevention Planning and Implementation for Metropolitan Statistical Areas Most Affected by HIV/AIDS (P30 AI027714, \$1,352,442) 2011 – 2013  
*Purpose: The goal of this project is to provide technical assistance to our local municipal Department of Health in support of the Enhanced Comprehensive HIV Prevention Planning (ECHPP) Initiative.*
- P.I., Varenicline for Methamphetamine Dependence (R01 DA030577, \$1,710,888) 2011 – 2014  
*Purpose: The goal of this project is to conduct a randomized, placebo-controlled, double-blind Phase II clinical trial of varenicline with a brief, inpatient detoxification period and cognitive behavioral therapy for the treatment of methamphetamine dependence.*
- Site P.I., HIV Prevention Trials Network 073: Pre Exposure Prophylaxis (PrEP) Uptake and Adherence among Black Men who have Sex with Men (BMSM) (5U01 AI069424, \$1,343,245) 2011-2015  
*Purpose: The goal of this project is to assess the uptake, acceptability, safety, and feasibility of PrEP for Black men who have sex with men (BMSM) utilizing client-centered care coordination (C4) models. This is an open label demonstration study.*
- Member, Executive Committee, HIV Prevention Trials Leadership Group (UM1 068619, \$248,913) 2011-2020  
*Purpose: The goal of the Leadership Group is to generate and review scientific priorities within Network vision of HIV/AIDS prevention, to identify gaps in scientific agenda, to identify site(s) for protocol participation, and to review manuscripts and discretionary proposals.*

- Co-Director, Combination Prevention Core, UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS; Rotheram-Borus 5P30 MH058107, \$1,220,290). 2012-2017  
*Purpose: CHIPTS is a collaboration of researchers from UCLA, Charles Drew University, Friends Research Institute, and RAND working with the broader L.A. community toward a common goal: to enhance the collective understanding of HIV research and to promote early detection, effective prevention, and treatment programs for HIV.*
- Co-Investigator, Bridging Research, Innovation, Training, & Education Solutions for Minority Health: Optimizing the Health of Korean Youth (PI: Mays, P60 MD006923, \$3million) 2012-2018  
*Purpose: The goal of this project is to significantly reduce morbidity in groups with disparities and to aid Los Angeles County and Healthy People 2020 in implementing a high impact, rigorous scientific agenda to optimize smoking cessation outcomes for Korean youth, a highly prevalent group.*
- Co-Investigator, Development of Ibudilast as a Novel Treatment for Alcoholism (R21 AA022214, \$221,375) 2013 – 2015  
*Purpose: The goal of this project is to advance medication development for alcoholism by conducting a safety and initial efficacy study of ibudilast, a neuroimmune modulator and phosphodiesterase inhibitor, for alcohol use disorders. This study has important clinical implications for the treatment of alcohol use disorders, as the available treatments are only modestly effective and testing novel medications is a high research priority.*  
 PI: Lara Ray
- Co-Investigator, Positive Deviance – Adaptive Strategies Among Young Black, HIV-Negative MSM (R03 DA035689, \$24,990) 2013-2016  
*Purpose: The goal of this two-year study is to (1) identify the range and nature of adaptive strategies for staying safe from HIV infection that are being used by low-income, drug-using young, black men who have sex with men (MSM), a group at the highest risk for HIV in the United States, (2) develop an adaptive strategies questionnaire, and (3) test the reliability and validity of the questionnaire.*  
 PI: Allison Ober
- Principal Investigator, Combating craving with contingency management: neuroplasticity and methamphetamine abuse in South Africa (R21 DA040492, \$292,897) 2015 – 2017  
*Purpose: The primary aim of this project is to determine whether functional changes in frontostriatal circuitry from baseline to end of treatment are associated with cognitive control and impulsivity in treatment-seeking MA users.*
- Principal Investigator, Randomized, Double-blind, Placebo-controlled trial of the safety and efficacy of Horizant® (Gabapentin Enacarbil) Extended-release Tablets for the Treatment of Alcohol Use Disorder (HHSN27500003-1061-NCIG6, \$1,451,805) 2015 – 2017  
*Purpose: The goal of this trial is to test whether the study drug, HORIZANT, is useful and safe for treating alcohol use disorders.*

Co-Investigator, HIV Prevention Trials Network 085, A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection (FHI 360 PO15004412, \$2,241,084) 2015 – 2020

*Purpose: The goal of this multicenter, randomized, controlled, double-blind trial is to evaluate the safety and tolerability of the VRC01 mAb administered through intravenous infusion and to determine if the VRC01 mAb prevents HIV-1 infection and to estimate the level of efficacy in each of 2 cohorts.*

Co-Investigator, HOPE Social Media Intervention for HIV Testing and Studying Social Networks (PI: Young, R01 MH106415) 2015-2018

*Purpose: This grant proposes to use social media for an HIV testing intervention among men who have sex with men (MSM) and study their changing social network characteristics.*

Site Investigator, Enhancing Enrollment and Retention in the US Phase II Clinical Trial: AMP (HPTN 085) Substudy (PI: Shoptaw, Fred Hutch Cancer Center PO0000888301, \$26,308) 2016-2018

*Purpose: The purpose of this project is to conduct qualitative interviews with participants of the HPTN 085 study who consented, but elected not to receive medication or who dropped from the study early in order to better understand their reasons for not participating.*

Co-Investigator, SNS-based Data Mining to Predict MSM Substance Use and HIV Risk Behavior (PI: Holloway, R03 DA039752, \$300,000) 2016-2020

*Purpose: The major goal of this project is to develop and assess the utility of a culturally congruent data collection and mining module (DCMM) to study the social networking site (SNS) use patterns, substance use and HIV risk and protective behaviors of gay, bisexual and other men who have sex with men (MSM). Data from this study will be used to inform just-in-time adaptive interventions to prevent incidence of new HIV cases among this population disproportionately impacted by HIV/AIDS*

Co-Investigator, Texas Node, Clinical Trials Network, Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder (PI: Trivedi, UG1DA020024-14S1) 2017–2019

*Purpose: This is a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Participants will be randomly assigned to the active medication combination (AMC) group or matching placebo group and will receive medications over the course of 12 weeks. Follow-ups will occur in weeks 13 and 16.*

### **ONGOING**

Co-Investigator, Social Networks and Drug Use Among Low-Income Students in High-Performing Schools (PI: Wong, 2R01DA0033362-06A1, \$501,126) 2012-2023

*Purpose: The RISE UP Study used the admission lottery of high-performing public charter high schools to study comparable cohorts of students exposed to high- and low-performing schools. This study aims to follow the RISE UP cohort through age 21 and examine the impact of exposure to a high performing school on substance use, pregnancy, depression,*

*obesity and other life events including employment, college matriculation and criminal arrests. Findings from this research have implications for how educational policies might be shaped to improve health, and specifically whether improving public high schools can help reverse the negative health effects of poverty.*

Percent Effort: 0% (Other Significant Contributor)

Co-PI, MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE; U01 DA036267) 2013– 2023

*Purpose: The goal of this project is to assemble a cohort of minority men who have sex with men (MMSM) who actively use substances and engage transmission risks. This will facilitate studies on interactions between substance use and HIV progression and/or transmission.*

Percent Effort: 10%

Clinical Research Site Leader, AIDS Prevention and Treatment Clinical Trials Unit, (5U01 AI069424, \$4,194,393) 2013– 2025

*Purpose: The major goals of this project are to support clinical trials research of the Adult Clinical Trials Group and HIV Prevention Trials Network at UCLA.*

Percent Effort: 5%

Co-Investigator, HIV Prevention Trials Network 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men (PI: Clark, FHI 360 PO 16002764 and FHI 360 PO 17001851) 2015-2021

*Purpose: To evaluate the safety and efficacy of the injectable agent, cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).*

Percent Effort: 0% (Effort for network projects is covered by AIDS Prevention and Treatment Clinical Trials Unit)

PI, UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS; P30 MH058107, \$1,228,100). 2017-2022

*Purpose: CHIPTS is a collaboration of researchers from UCLA, Charles Drew University, Friends Research Institute, and RAND working with the broader L.A. community toward a common goal: to enhance the collective understanding of HIV research and to promote early detection, effective prevention, and treatment programs for HIV.*

Percent Effort: 30%

Co-Investigator, A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder (PI: Ray, R01 AA026190) 2018-2021

*Purpose: Building upon the strong rationale and preclinical findings for Ibudilast, along with safety data and early efficacy in human testing, this proposal seeks to conduct a 12-week, double-blind, placebo controlled randomized clinical trial of Ibudilast for the treatment of alcohol use disorder.*

Percent Effort: 0% Other Significant Contributor



- Co-Investigator, Disparities in Rates and Impact of Tobacco and Marijuana in UCLA Primary Care (PI: Gelberg, Tobacco-Related Disease Research Program T29IR0277) 2019-2021  
*Purpose: The major goals of this study are to assess rates of tobacco and marijuana use and second hand smoke exposure in all UCLA Primary Care patients of all ages, after we implement self-administered, computerized, screening via the patient portal.*  
Percent Effort: 0% Other Significant Contributor
- Co-Investigator, Technology Improving Success of Medication-Assisted Treatment in Primary Care (PI: Jenkins, R42 DA050398) 2019-2022  
*Purpose: The goal of this project is to modify the Opioid Addiction Recovery Support (OARS) platform for use in primary care settings and then to employ a “stepped wedge” design to assess the effectiveness of OARS in improving opioid agonist treatment outcomes across 6 treatment programs, as well as to evaluate sustainability and return on investment of OARS implementation.*  
Percent Effort: 2%
- Co-Investigator, uTECH: Machine Learning for HIV Prevention Among Substance Using GBMSM (PI: Holloway, DP2DA049296 ) 2019-2024  
*Purpose: The purpose of this grant is to conduct a two-phase study. In Phase 1 we will conduct qualitative interviews with GBMSM to inform the iterative development and refinement of uTECH. In Phase 2, we will test the acceptability, appropriateness and feasibility of uTECH in a comparative implementation science trial.*  
Percent Effort: 0% Other Significant Contributor
- MPI, Screen, Treat and Retain Meth-Using People with Opioid Use Disorders at MMT Clinics (STAR-OM) (PI: Le, R01 DA050486) 2020-2023  
*Purpose: The proposed study will develop and evaluate the optimal combination of evidence-based interventions (EBIs) to reduce methamphetamine (hereafter: meth) use and improve HIV prevention and care outcomes among opioid drug users (ODUs) in Vietnam.*  
Percent Effort: 7%
- Co-PI, Big South/West Node, Clinical Trials Network (PI: Trivedi, Shoptaw, Potter) 2020-2025  
 UG1DA020024)  
*Purpose: The NIDA CTN cooperatively develops, validates, refines and delivers new treatment options to patients. The Big South/West Node builds upon our investigators’ expertise in treating stimulant and opioid use disorders, and the changing needs of the regions we serve which spans diverse and underserved geographic areas.*  
Percent Effort: 20%
- Protocol Team Lead, HPTN 094 INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care (PI: Shoptaw, FHI 360 PO21000095) 2020-2025  
*Purpose: To carry out a vanguard study of health service delivery in a mobile health delivery unit to link persons who inject drugs to integrated care and prevention for addiction, HIV, HCV and primary care.*  
Percent Effort: 10%

**PENDING**

Co-Investigator, Mirtazapine for methamphetamine use disorder: drug-drug interaction study (PI: Coffin) 2020-2022

*Purpose: The primary goal of this study is to determine if mirtazapine 30mg daily alters the cardiovascular response to IV meth. The interaction of active medication (compared with placebo) with relevant doses of meth (30 mg) on cardiovascular (heart rate, blood pressure) parameters will be assessed to gather safety information in the Phase I human laboratory.*

Clinical Research Site Leader, CoVPN 3001/Moderna: A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older (PI: Clark, FHI 360 PO20002746) 2020-2022

*Purpose: The purpose of this trial is to demonstrate the efficacy of mRNA-1273 to prevent COVID-19 and to evaluate its safety and reactogenicity.*

**LECTURES AND PRESENTATIONS:**

Supervisor of Psychology Tutors, Academic Advancement Program, UCLA. Hired and trained psychology tutors to provide services to 300 students. Conducted in-house workshops pertaining to improving communication skills and to referring students needing psychological intervention. Aug 1982 – Sept 1983

Graduate Teaching Associate, UCLA. Led discussion groups for "Counseling Relationships." Oct 1985 – Jun 1990

Course Instructor, UCLA. Responsible for developing syllabus and course materials for upper-division, undergraduate class, "Counseling Relationships." Prepared and delivered five lectures per quarter. Assigned grades for 60 students per term. Sept 1987 – Jun 1990

Instructor, University of Judaism, Continuing Education. Instructed class entitled, "The Intimate Science of Communicating in Close Relationships." Jan 1991 – Dec 1991

Seminar in family therapy, Glen Roberts Child Study Center, Glendale, CA. Led five week January, 1994 training seminar on family therapy to graduate student interns. Jun 1992 – May 1999

Dissertation Chair/Committee member. Guide dissertation research on substance abuse treatment evaluation and HIV prevention projects for graduate students. Sept 1992 – Present

Shoptaw, S., Rawson, R.A., McCann, M.J. (1993). *The Behavioral Change Index: A new assessment tool for addicted populations*. Presented at the 55th Annual Meeting of the College on Problems of Drug Dependence, Toronto, Canada. June. June 1993

Rawson, R.A., Shoptaw, S., McCann, M.J., Minsky, S. (1993). *Characteristics of stimulant addicts who responded positively to outpatient treatment*. Presented at the 55th Annual June 1993

- Meeting of the College on Problems of Drug Dependence, Toronto, Canada. June.
- Obert, J., Shoptaw, S., Rawson, R., McCann, M. (1993). *Retention, engagement, and psychosocial outcomes for subjects in neurobehavioral treatment for stimulant dependence*. Presented at the 55th Annual Meeting of the College on Problems of Drug Dependence, Toronto, Canada. June. June 1993
- Nagata, T., Shoptaw, S., Rawson, R., Minsky, S. (1993). *Cultural influences on self-reported HIV risk behaviors during psychosocial drug treatment*. Presented at the 55th Annual Meeting of the College on Problems of Drug Dependence, Toronto, Canada. June. June 1993
- Training Instructor, Drug and Alcohol Abuse Certifications. Train mental health professionals (e.g., Ph.D. and M.A.) candidates for state licensure in drug and alcohol abuse counseling issues. Trainings have been conducted city-wide. Oct 1993 – Present
- Shoptaw, S., Rawson, R., Anglin, M.D., Grella, C. (1994). *Effectiveness of integrating enhancements to standard methadone treatment for subjects at high risk for HIV transmission*. Paper presented at the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Beach, FL. June. June 1994
- Rawson, R., Shoptaw, S., Obert, J., McCann, M. (1994). *Effectiveness of desipramine in treating cocaine dependence*. Paper presented at the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Beach, FL. June. June 1994
- Ling, W., Klett, J., Rawson, R., Shoptaw, S. (1994). *A composite score for evaluating treatment response in cocaine pharmacotherapy trials*. Paper presented at the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence, Palm Beach, FL. June. June 1994
- Shoptaw, S., Rawson, R.A., Huber, A., Frosch, D., Nagata, T., Ling, W. (1995). *Substance abuse treatment as an HIV prevention strategy for stimulant addicts*. Paper presented at the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. June. June 1995
- Shoptaw, S., Jarvik, M.E., Rawson, R.A., Ling, W. (1995). *Contingency management for smoking cessation among methadone maintained addicts: A pilot study*. Paper presented at the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. June. June 1995
- Shoptaw, S., Frosch, D., Rawson, R.A., Portnoff, M. (1996). *Comparisons of drug-free and methadone counselors who treat substance abusers with HIV*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- Rawson, R.A., McCann, M.J., Huber, A., Shoptaw, S., Miotto, K., Ling, W. (1996). *Protocol to facilitate naltrexone treatment for opiate addiction*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996

- Rawson, R.A., Huber, A., McCann, M., Hasson, A., Shoptaw, S., Ling, W. (1996). *Two years after the NDA: Extent of LAAM usage*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- Raisch, D.W., Jones, M.S., Garnand, D., Johnson, E.L., Sather, M.R., Ling, W., Huber, A., Shoptaw, S. (1996). *Remote drug transfer information system in a trial comparing buprenorphine sublingual liquid to tablets*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- McCann, M.J., Rawson, R.A., Shoptaw, S., Huber, A., Miotto, K., Ling, W. (1996). *Outpatient clonidine/oxazepam detoxification for opioid withdrawal: Completers characteristics*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- Ling, W., Huber, A., Shoptaw, S., Charuvastra, V.C., Bridge, P., Chiang, N., Herbert, S., Dow, S., Compton, P. (1996). *First clinical experience with buprenorphine-naloxone combination sublingual tablet*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- Jarvik, M.E., Madsen, D., Shoptaw, S., Frosch, D. (1996). *Ambient and outdoor carbon monoxide levels among non-smokers in Los Angeles*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- Gudeman, D., Shoptaw, S., Majewska, D., Scherf, S., Yeats, D., Ling, W. (1996). *Preliminary report of baclofen as a cocaine craving medication*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- Frosch, D., Shoptaw, S., Rawson, R.A., Ling, W. (1996). *Preliminary report on sexual HIV risk behaviors among urban gay male methamphetamine abusers*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- Shoptaw, S., Jarvik, M.E., Ling, W., Rawson, R.A. (1996). *Contingency management for tobacco smoking in methadone maintained opiate addicts*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- Annon, J., Anglin, M.D., Danila, B., Annon, K., Shoptaw, S., Ling, W., Rawson, R. (1996). *HIV-related risk behaviors among homosexual and heterosexual recent arrestees*. Paper presented at the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 1996
- McCann, M., Rawson, R.A., Miotto, K., Obert, J., Shoptaw, S., Huber, A., Ling, W. (1997). *Opioid dependence treatment with naltrexone: Value of a manualized psychosocial protocol*. Paper presented at the 28th Annual Medical-Scientific Conference of the American Society of Addiction Medicine; San Diego, CA. 1997

- Shoptaw, S., Nahom, D., Frosch, D., Portnoff, M., Rawson, R.A., Ling, W. (1997). *Efficacy of structured manual for improving drug counseling among substance abusers with HIV*. Paper presented at the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence, Nashville, TN. June. June 1997
- Frosch, D., Shoptaw, S., Jarvik, M.E., Rawson, R.A., Ling, W. (1997). *Preliminary experiences with opiate abusers seeking smoking cessation treatment*. Paper presented at the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence, Nashville, TN. June. June 1997
- Rawson, R., Ling, W., Shoptaw, S., Huber, A., Dow, S. (1997). *AIDS-related drug and sexual risk behaviors: What drugs and which routes?* Presented at the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence, Nashville, TN. June. June 1997
- Nahom, D., Shoptaw, S., Charuvastra, V.C., Ajir, K., Ling, W. (1997) *Methadone dose effects on treatment efficacy*. Paper presented at the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence, Nashville, TN. June. June 1997
- Shoptaw, S. (1997). *Chemical dependency and communicable diseases*. September. September 1997
- Shoptaw, S., Frosch, D. (1997). *Substance abuse treatment as HIV prevention for men who have sex with men*. September 4. September 4, 1997
- Shoptaw, S. (1997). *Intervention strategies for gay/bisexual male crystal users*. November 1. November 1, 1997
- Shoptaw, S. Reback, C., Freese, T., Ling, W. (1998). *Treatment effects on HIV-related risk behaviors for MSM*. Paper presented at the American Psychological Association (APA) Public Interest Miniconvention on HIV/AIDS, San Francisco, CA. 1998
- Shoptaw, S., Kintaudi, P.C., Charuvastra, C.V., Rawson, R.A., Ling, W. (1998). *Amantadine hydrochloride is effective treatment for cocaine dependence*. Paper presented at the 60th Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. June. 1998
- Shoptaw, S. (1998). *Research career options for psychology majors*. February. February 1998
- Huber, A., Shoptaw, S., Rawson, R.A., Brethen, P., Ling, W. (1998). *Methamphetamine: User characteristics and treatment response*. March 17. March 17, 1998
- Shoptaw, S., Reback, C. (1998). *Treatment for crystal-using gay and bisexual men*. May 6. May 6, 1998
- Shoptaw, S., Ling, W., Kintaudi, K., Klett, J. (1998). *Rapid evaluation of cocaine pharmacotherapy: Amantadine*. June. June 1998
- Gulati, V., Huber, A., Reback, C., Shoptaw, S., Freese, T., Rawson, R. (1998). *HIV risk behaviors of methamphetamine users*. Presented at the 60th Annual Scientific Meeting of the

College on Problems of Drug Dependence, Scottsdale, AZ. June.

- Kalechstein, A. D., Newton, T. F., Shoptaw, S., & Ling, W. (1998). *The neuropsychological sequel of methamphetamine dependence in recently abstinent individuals: A preliminary report*. Paper presented at the 60th Annual Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. June. June 1998
- Frosch, D.L., Shoptaw, S., Nahom, D., Ling, W., Jarvik, M.E. (1998). *Differences in drug use among methadone maintained tobacco chippers and heavy smokers*. Presented at the 60th Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. June. June 1998
- Freese, T., Shoptaw, S., Huber, A., Rawson, R., Ling, W. (1998). *Drug Treatment and HIV risk: It's not just about needles anymore*. Presented at the 60th Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ. June. June 1998
- Nahom, D., Shoptaw, S., Frosch, D., Jarvik, M.E., Rawson, R.A., Ling, W. (1998). *Successful smoking cessation among methadone-maintained tobacco smokers*. June 8. June 8, 1998
- Shoptaw, S. (1998). *Evaluations of cocaine medications*. Presented at the Long Beach Research Foundation, July 22. July 22, 1998
- Sreenivasan, S., Shoptaw, S., Kirkish, P., Welsh, R. (1998). *Neuropsychological, personality and substance abuse differences between recidivistic violent criminally insane and mentally ill prisoners*. September. September 1998
- Chernin, J., Larkins, S., Freese, T., Shoptaw, S., Peck, J., Hucks-Ortiz, C., Kelly, A. (1999). *Methamphetamine: From the streets, to the clinic, to the community: The gay/bisexual male experience*. Presented at the CPA Convention, San Diego, CA. 1999
- Shoptaw, S. (1999). *Cigarette smoking cessation in vulnerable populations: Opiate dependent individuals*. University of Southern California, January 29. January 29, 1999
- Shoptaw, S., Reback, C.J., Eggan, F., Freese, T.E., Kelly, A., & Peck, J. (1999). *Methamphetamine from the streets to the clinic to the community: The gay/bisexual male experience*. Presented at the 52nd Annual Convention of the California Psychological Association. March 28, San Diego, CA. March 28, 1999
- Shoptaw, S., Freese, T., Huber, A., Reback, C. (1999). *HIV risk behaviors*. Presented at the American Society of Addiction Medicine's 30th Annual Medical-Scientific Conference, New York, New York. April. April 1999
- Huber, A., Shoptaw, S., Freese, T.E., Reback, C.J. (1999). *Overview of AIDS/HIV and drug use rates in the U.S.* Presented at the Conference of the American Society of Addiction Medicine, May. May 1999

- Shoptaw, S. (1999). *Substance abuse treatment as HIV risk reduction*. Presented at the Conference of the American Society of Addiction Medicine, May. Scott, R.L., Shoptaw, S., Miotto, K. (1999). *Crack use, sexuality, and HIV-risk behaviors among African-Americans in Los Angeles*. Presented at the Conference of the American Society of Addiction Medicine, May. May 1999
- Reback, C., Shoptaw, S., Newton, T. (1999). *Crystal methamphetamine and gay men: Science and community*. June. June 1999
- Shoptaw, S., Rotheram-Fuller, E., Frosch, D., Jarvik, M., Rawson, R., Ling, W. (1999). *Smoking cessation in methadone maintenance: Evaluation of nicotine replacement and behavioral therapies*. Presented at the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence, Acapulco, Mexico. June. June 1999
- Shoptaw, S., Ling, W., Kintuadi, K. (1999). *Outcomes when using the GABA-B agonist baclofen in human cocaine abusers*. Paper presented at the 61st Annual Conference of College on Problems of Drug Dependence, Acapulco, Mexico. June. June 1999
- Shoptaw, S. & Reback, C.J. (1999). *Crystal methamphetamine and gay Men: Empirical findings*. Paper presented at City of West Hollywood Community Forum on Crystal Methamphetamine. June 23. June 23, 1999
- Instructor, UCLA Extension. Teach average of two courses for UCLA Extension: Communicable Disease and Chemical Dependency; HIV and Chemical Dependency. Course ratings 8.9 of 9.0. Sept 1999 – Present
- Reback, C.J., Shoptaw, S., Freese, T.E., Larkins, S.L., & Hucks-Ortiz, C. (1999). *Preliminary treatment outcomes for gay and bisexual male methamphetamine users in Los Angeles, CA*. Poster presented at American Public Health Association. Chicago, IL, November. November 1999
- Shoptaw, S., Reback, C.J., Larkins, S. (1999). *Behavioral therapies for gay male stimulant abusers*. November 2. November 2, 1999
- Shoptaw, S., Reback, C.J., & Freese, T.E. (1999). *Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles*. Poster presented at CSAT Methamphetamine Conference. Honolulu, HI, December. December 1999
- Shoptaw, S. (2000). *Combining substance abuse treatment and HIV prevention for men who have sex with men who inject crystal methamphetamine*. Paper presented at “A Comprehensive Approach to Effective HIV Prevention for IDUs”, at the CDC-sponsored, “2000 Community Planning HIV Leadership Summit Institute”, Los Angeles, CA. March 31. March 31, 2000
- Shoptaw, S., Ling, W., Twitchell, G., Wilkins, J., Majewska, M. (2000). *DHEA as a cocaine pharmacotherapy: Preliminary results of a randomized placebo-controlled trial*. Paper presented at the 62nd Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 2000

- Huber, A., Shoptaw, S., Gulati, V., Gonzales, R. (2000). *Sertraline and contingency management as treatment for methamphetamine dependence*. Presented at the 62nd Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 2000
- Reback, C.J., Larkins, S., Shoptaw, S. (2000). *A qualitative analysis of drug and sexual HIV risks as an outcome of treatment among gay male methamphetamine users*. Presented at the 62nd Annual Scientific Meeting of the College on Problems of Drug Dependence, San Juan, PR. June. June 2000
- Chiappelli, F., Hucks-Ortiz, C., Younai, F., Liu, N., Reback, C., Shoptaw, S., Freese, T., Ling, K. (2000). *The impact of methamphetamine use on immune functioning in a sample of treatment-seeking gay and bisexual men*. Poster presented at College on Problems of Drug Dependence, San Juan, PR. June. June 2000
- Freese, T. E., Reback, C., Huber, A., Shoptaw, S., Peck, J. (2000). *The impact of methamphetamine use on HIV risk behaviors in homosexual men and heterosexual men and women*. Poster presented at College on Problems of Drug Dependence, San Juan, PR. June. June 2000
- Shoptaw, S. (2000). *Sexual issues in drug abuse treatment: Clinical assessment and intervention*. San Mateo, CA. June 16. June 16, 2000
- Shoptaw, S., Twitchell, G., Reback, C., Gulati, V., Freese, T., Huber, A. (2000). *Detailed behavioral risk assessments discriminate between gay/bisexual HIV infected and HIV uninfected methamphetamine abusers in Los Angeles*. July. July 2000
- Shoptaw, S., Rotheram-Fuller, E.R., Frosch, D.L., Nahom, D., Jarvik, M., Rawson, R.A., Ling, W. (2000). *Tobacco smoking abstinence and abstinence from illicit drug use among methadone-maintained opiate dependent individuals*. July 24. July 24, 2000
- Blum, M., Shoptaw, S., Reback, C. (2000). *Women who have sex with women: HIV risk behavior and substance abuse treatment needs*. July 28. July 28, 2000
- Freese, T.E., Shoptaw, S., Reback, C.J., Larkins, S., Twitchell, G. (2000). *Outcomes of interventions for gay and bisexual male methamphetamine users*. Presented at the Gay and Lesbian Medical Association, August. August 2000
- Shoptaw, S. (2000). *Immune correlates among gay and bisexual male methamphetamine abusers*. Presented at the ISAP Scientific Meeting September 8. Los Angeles, CA. September 8, 2000
- Shoptaw, S., Chiappelli, F., Reback, C., Ling, W., Twitchell, G., Freese, T., Hucks-Ortiz, C., Rawson, R., Ling, W. (2000). *Immune correlates among gay and bisexual male methamphetamine abusers*. Presented at UCLA's Integrated Substance Abuse Programs' Weekly Scientific Meeting, September 8. September 8, 2000
- Shoptaw, S. (2000). *Medications development for substance dependence: Clinical implications*. October. October 2000



- Shoptaw, S. (2001). *Strategic plan to guide HIV research in the CTN. HIV/AIDS Workgroup of the CTN.* 2001
- Shoptaw, S., Moe, A., Reback, C., Rotheram-Fuller, E., Kanouse, D., McGee-Smith, D. (2001). *Post exposure prophylaxis as an HIV biobehavioral prevention intervention.* January. January 2001
- Shoptaw, S., Reback, C., Moe, A., Kintaudi, P. (2001). *Post-exposure prophylaxis as a biobehavioral HIV prevention intervention.* February 13. February 13, 2001
- Shoptaw, S., Huber, A., Reback, C.J., Rotheram-Fuller, E., Rawson, R.A. & Ling, W. (2001). *Psychiatric comorbidity and drug-related characteristics in two samples of treatment-seeking methamphetamine abusers in Los Angeles.* Poster presented at College on Problems of Drug Dependence, June 17. June 17, 2001
- Reback, C. J., Larkins S. & Shoptaw, S. (2001). *A qualitative analysis of HIV medication adherence among gay men in treatment for methamphetamine abuse.* Poster presented at College on Problems of Drug Dependence, June 18. June 18, 2001
- Hucks-Ortiz, C., Shoptaw, S. & Reback, C.J. (2001) *Association between methamphetamine and high-risk behaviors among gay and bisexual men in Los Angeles.* Presentation made at College on Problems of Drug Dependence, June 21. June 21, 2001
- Shoptaw, S. (2001). *A "snapshot" of HIV/AIDS related services in clinical treatment providers for NIDA's Clinical Trials Network: A report submitted to the Steering Committee of the Clinical Trials Network by the HIV/AIDS Workgroup.* July 17. July 17, 2001
- Shoptaw, S. (2001). *New research in the psychopharmacological treatment of substance abuse and smoking cessation.* Presented at the University of California, Los Angeles. October. October 2001
- Shoptaw, S. (2001). *Designing smoking cessation programs for behavioral health clients: GLBT smokers.* October. October 2001
- Shoptaw, S. (2001). *Nicotine addiction among the seriously mentally ill and substance-abusing populations: The epidemiology and biochemistry of addiction.* Presented to the Ventura County Conference on Nicotine Dependence, October 26. October 26, 2001
- Shoptaw, S. (2001). *Nicotine addiction.* November. November 2001
- Shoptaw, S., Reback, C., Yang, X., Rotheram-Fuller, E., Peck, J., Larkins, S. (2002). *Differential outcomes in a randomized trial of behavioral drug therapies for reducing drug use and sexual risk behaviors among gay and bisexual male methamphetamine abusers in Los Angeles.* Presented at the XIV International AIDS Conference, Barcelona, Spain. 2001
- Shoptaw, S. (2002). *Reducing drug- and sex-related HIV risk in gay male methamphetamine users.* Presented at UCLA's Integrated Substance Abuse Programs' Weekly Scientific February 1, 2002

Meeting, February 1, 2002.

- Shoptaw, S. (2002). *A Phase 2, double-blind, placebo-controlled trial of cabergoline for the treatment of cocaine dependence*. February 11. February 11, 2002
- Shoptaw, S. (2002). *Treatment approaches for co-morbid substance dependence. Lecture: "Biological Perspectives on Dual Diagnosis"*. University of California, Los Angeles, March 4. March 4, 2002
- Shoptaw, S., Meadors, G., Veniegas, R. (2002). *Evidence based treatments for use in community settings*. Presented at Friends at Mt. Carmel, April 12. April 12, 2002
- Shoptaw, S. (2002). *Medication development for stimulant dependence: Baclofen*. Presented at Battelle, Arlington, VA., November 19, 2002. November 19, 2002
- Shoptaw, S. (2003). *Cigarette smoking cessation invulnerable populations opiate dependent individuals*. University of Southern California, February 19. February 19, 2003
- Instructor. Phillips Graduate Institute. Designed and taught 2-unit, intensive course on statistics to students in doctoral program in psychology. Also taught courses in Applied Research Methods and Tests and Measurements. Teaching ratings average 3.7 of 4.0. Jun – Jul 2003
- Shoptaw, S., Reback, C. (2003). *Behavioral drug abuse treatment reduces HIV risk behaviors in methamphetamine-abusing MSM*. Long Beach Health Department, October 17. October 17, 2003
- Shoptaw, S. (2003). *Update on treatment of cocaine and methamphetamine abuse*. Strickland Conference at the Radisson, LAX. October 24. October 24, 2003
- Shoptaw, S., Reback, C. (2003). *Methamphetamine, HIV, and gay and bisexual men: Behavioral interventions*. Long Beach Care Program, October 29. October 29, 2003
- Peck, J.A., Shoptaw, S., Reback, C.J. (2003). *Intertwining epidemical: HIV/AIDS among methamphetamine-abusing men who have sex with men*. Invited address, California Office of AIDS, HIV Planning Council, San Diego, CA, November 6. November 6, 2003
- Shoptaw, S. (2005). *Medication(s) for treating cocaine abuse*. Charles R. Drew University of Medicine & Science. Los Angeles, CA. July 28. July 28, 2005
- Shoptaw, S. (2005). *Methamphetamine abuse in gay and bisexual men: From research to policy*. Substance Abuse Research Consortium, Sacramento, CA. September 14. September 14, 2005
- Shoptaw, S. (2005). *Drug abuse treatment as HIV prevention*. NIDA HIV/AIDS Drug Abuse Science Meeting. Washington, D.C., November 29. November 29, 2005
- Shoptaw, S. (2006). *Men who have sex with men, club drugs and HIV*. American Psychological Association. Memphis, TN. January 27. January 27, 2006

Shoptaw, S. (2006). <i>Methamphetamine use in HIV-infected patients</i> . International AIDS Society, Improving the Management of HIV Disease Los Angeles, CA. February 23.	February 23, 2006
Larkins, S, Reback, C, & Shoptaw, S. (2006). <i>Planned non-adherence among gay male methamphetamine users</i> . International Association of Physicians for AIDS Care, NIMH Meetings, Jersey City, NJ: March	March 2006
Shoptaw, S., Reback, C., Rawson R., (2006). <i>Methamphetamine abuse: Treatment as prevention</i> . 16th Annual Clinical Care Options for HIV Symposium. Key Biscayne, FL. May 6.	May 6, 2006
Shoptaw, S. (2006). <i>Crystal methamphetamine 101 for physicians</i> . Cedars Sinai Medical Center Office of Continuing Medical Education. Los Angeles, CA June 23.	June 23, 2006
Shoptaw, S. (2006). <i>Evidence-based intervention strategies for methamphetamine users in HIV care settings</i> (2006). 9th Annual Ryan White CARE Act Clinical Conference. Washington, D.C., August 28.	August 28, 2006
Shoptaw, S. (2007). <i>Managing methamphetamine abuse in the setting of HIV infection</i> . The HIV Dialogues, Gilead. Toronto, Canada. September 7.	September 7, 2007
Instructor. Substance Abuse In Methamphetamine Treatment. Venice Family Clinic. Santa Monica, CA	Feb 2008 – Present
Shoptaw, S. (2008). <i>Practical smoking cessation in methadone treatment programs</i> . Synergy Enterprise Inc., Toronto, Canada, April 12	April 12, 2008
Shoptaw, S. (2008). <i>Methamphetamine and HIV national summit to promote public health</i> . Washington, DC, November 17.	November 17, 2008
Shoptaw, S. (2008). <i>Methamphetamine use &amp; HIV infection</i> . Cleveland Department of Veterans Affairs. Cleveland, OH, November 19.	November 19, 2008
Shoptaw, S. (2008). <i>The epidemic moved on: Findings from a sample of very poor MSM and drug users in Los Angeles</i> . UCLA AIDS Institute, Los Angeles, CA December 4.	December 4, 2008
Shoptaw, S. (2009). <i>Speeding out of Control: All you need to know and its consequences</i> . Tarzana Treatment Center, Antelope Valley, CA. January 9.	January 9, 2009
Instructor. Psychiatry 295B. Drug Abuse Intersects HIV: Using Evidence to Guide U.S. Prevention Strategy. UCLA Integrated Substance Abuse Program.	February 20, 2009
Instructor. RDS Presentation to UCLA School of Nursing	March 17, 2009
Shoptaw, S. (2009). <i>Drug using MSM: Recruitment strategies in Los Angeles</i> . NIDA MSM Recruitment Meeting. Bethesda, MD, April 28.	April 28, 2009

Shoptaw, S. (2009). <i>Managing patients addicted to crystal methamphetamine</i> . 19th Annual Clinical Care Options HIV Symposium. Miami, FL, May 2.	May 2, 2009
Instructor. Substance Abuse. UCLA Department of Psychology	May 20, 2009
Instructor. HIV/AIDS & Drug Use in the United States: A Domestic Agenda. UCLA Dept. of Public Health	May 22, 2009
Instructor, HIV and Substance Abuse: Focus on Stimulants. UCLA PAETC Dept.	June 29, 2009
Clinical Supervisor. Clinical Practicum. Psychology 401. UCLA Psychology Clinic.	Aug 2009 – Present
Shoptaw, S. (2009). <i>Methamphetamine and the brain</i> . San Gabriel Meth Task Force. Los Angeles, CA, September 1.	September 1, 2009
Shoptaw, S. (2009). <i>HIV and stimulant use in a sample of ethnic drug-using men who have sex with men and women in Los Angeles</i> . ISAM Conference. Calgary, Canada, September 24.	September 24, 2009
Shoptaw, S. (2009). <i>Methamphetamine and youth</i> . Pueblo Learning Center, Palmdale, CA, September 29.	September 29, 2009
Shoptaw, S. (2009). <i>Special risk factors for substance abuse in the LGBT population</i> . ASAM Conference. Washington DC, October 24.	October 24, 2009
Shoptaw, S. (2009). <i>Medication for methamphetamine dependence</i> . APSAD Conference. Darwin, Australia. November 4.	November 4, 2009
Shoptaw, S. (2009). Injection drug use and harm reduction. Physicians for Human Rights Group. Los Angeles, CA. November 9.	November 9, 2009
Instructor, Reducing HIV-Risk Behaviors via Drug Use Reduction. UCLA Department of Psychology & Biobehavioral Science	January 12, 2010
Instructor, Overview of Substance Abuse Issues. Venice Family Clinic	February 3, 2010
Instructor, Medication for Methamphetamine Dependence, Directions for Treatment & Research. UCLA Addiction Psych Seminar	February 4, 2010
Shoptaw, S. (2010). <i>Crystal meth &amp; the brain</i> . Prototypes Pomona. Pomona, CA March 28.	March 28, 2010
Shoptaw, S. (2010). <i>Homelessness and substance abuse and mental illness</i> . Hope for Homeless. Los Angeles, CA April 9.	April 9, 2010
Instructor, Methods In Recruiting Hidden Populations: RDS And Community Referred.	April 13, 2010

School of Public Health, UCLA

Instructor. Substance Abuse, UCLA, Department of Psychology	May 17, 2010
Instructor. Substance Use and STIs/HIV, UCLA Department of Epidemiology, EPI 227	May 19, 2010
Landovitz, R., Shoptaw, S., Reback, C., (2010). <i>Contingency management facilitates HIV post-exposure prophylaxis in methamphetamine-using MSM</i> . College on Problems of Drug Dependence. Poster Presentation, Scottsdale, AZ June 17.	June 17, 2010
Reback, C., Shoptaw, S. (2010). <i>Characteristics of treatment responders to a contingency management intervention for homeless, out-of-treatment, substance-dependent men who have sex with men</i> . Poster Presentation, Scottsdale, AZ June 17.	June 17, 2010
Instructor, Stimulant Abuse Treatments as HIV Prevention Strategies. CALDAR Summer Institute Day	August 11, 2010
Instructor, Methamphetamine and HIV; Toward a Biological Understanding. UCLA CARE Center	August 30, 2010
Instructor, Job Skills. International Medical Group Students. UCLA Family Health Center.	October 20, 2010
Shoptaw, S. (2010). <i>Initial findings from two HIV prevention projects in Los Angeles: Young MSM and black MSM (HPTN 061)</i> . 14th National CFAR Conference, University of California, Los Angeles, Los Angeles, CA. November 4.	November 4, 2010
Instructor, Ibutilast: A Novel Direction to Treatment for Methamphetamine. UCLA Addiction Psych Seminar	November 17, 2010
Instructor, Motivational Interviewing. Casa Pacifica.	January 13, 2011
Shoptaw, S. (2011). <i>Initial findings from two HIV prevention projects in Los Angeles: Young MSM and black MSM (HPTN 061)</i> . Health, Hope and Healing Conference, University of California, Los Angeles. Los Angeles, CA. February 1.	February 1, 2011
Instructor, Evidence-Based Interventions: Substance Abuse & Dependence. Venice Family Clinic.	February 2, 2011
Instructor, Addiction Medicine Clinical Rounds, UCLA Semel Institute.	April 7, 2011
Instructor, Job Skills. International Medical Group Students. UCLA Family Health Center.	April 16, 2011
Instructor, Research Methods in the Social and Behavioral Determinants of AIDS Prevention. CHS293	April 26, 2011

Instructor. Substance Use and STIs/HIV, UCLA Department of Epidemiology, EPI 227	<i>Shoptaw, Steven J., Ph.D.</i> May 13, 2011
Instructor. In-Service: Suicidal/High Risk Patients. UCLA Family Health Center.	June 15, 2011
Shoptaw, S. (2011). <i>Conference on resilience in gay/bisexual men</i> . Fenway Health, Boston, MA. June 23.	June 23, 2011
Shoptaw, S (2011). <i>Treatment as Prevention for Substance Users and MSM</i> . Substance Use, Mental Health, and HIV: Integrating Treatment as Prevention Conference, Atlanta, GA. August 14	August 14, 2011
Shoptaw, S. (2011). <i>Treatment as prevention: Can it work in Asia Conference</i> . University of California, Los Angeles. Busan, Korea. Treatment as Prevention. August 25.	August 25, 2011
Instructor, Applied Statistics, UCLA Fellows in Addiction Medicine in Primary Care	Oct 2011 – Jan 2012
Instructor, Overview of Substance Abuse Issues. Venice Family Clinic	January 11, 2012
Instructor. Safety, Limits and Difficult Patients. Harbor UCLA Medical Center’s Clinical Translational Research Center.	April 12, 2012
Instructor. Conditional Cash Transfers – Contingency Management. AIDS Seminar. UCLA Department of Biostatistics, School of Public Health	May 1, 2012
Shoptaw, S. (2012). <i>Baseline findings from the HPTN061 BROTHERS Project: Participant characteristics</i> . Los Angeles County HIV Prevention Planning Committee meeting. St. Anne’s Foundation Room, Los Angeles, CA. May 3.	May 3, 2012
Instructor. Epidemiology of Substance Use; Measurement and Analysis. Behavioral Epidemiology Course. UCLA School of Public Health.	May 14, 2012
Shoptaw, S. (2012). <i>Medical marijuana debate moderator</i> . Coping with Hope 2012: HIV, Health Care Reform and Mental Health. California Endowment. Los Angeles, CA. May 17.	May 17, 2012
Instructor. Drug Abuse and HIV/AIDS in the United States. UCLA Department of Epidemiology, EPI 227.	May 18, 2012
Shoptaw, S. (2012). <i>Current knowledge about substance abuse treatment for LGBT populations</i> . LGBT Summer Institute at the University of Pittsburg, Pittsburg, PA. June 18.	June 18, 2012
Shoptaw, S. (2012). <i>Drugs, alcohol and your children: What do you need to know?</i> UCLA Family Commons, Santa Monica, CA. August 1.	August 1, 2012
Shoptaw, S. (2012) <i>Translation from Pre-Clinical to Phase I Clinical Studies in Methamphetamine Medication Development: The Case for Ibudilast</i> . National Hispanic	September 28, 2012

- Science Network on Drug Abuse Annual Conference, Miami, FL. September 28.
- Shoptaw, S. (2012). *Addressing the methamphetamine epidemic*. Addiction and Recovery: Strategies for Practitioners, Union of American Physicians and Dentists (UAPD) and the California Society of Addiction Medicine, San Francisco, CA. November 2, 2012
- Shoptaw, S. (2012). *Current Challenges in Behavioral Economics*. School of Social Work, Columbia University, New York, NY. November 19, 2012
- Instructor. Addiction and Primary Care. UCLA School of Public Health. February 12, 2013
- Shoptaw, S. (2013). *Correlates of health and HIV infection among black MSM in Los Angeles*. NIDA's Special Populations Office and the AIDS Research Program, Bethesda, MD. February 19, 2012
- Shoptaw, S. (2013). *Findings from HIV Prevention Trials Network 061 Study: Using data to set HIV prevention priorities in Los Angeles*. LA County HIV Commission/HIV Prevention Planning Committee meeting, Los Angeles, CA. April 11, 2013
- Shoptaw, S. (2013). *Topic: HIV prevention in substance users*. International Conference on Global Health: Prevention and Treatment of Substance Use Disorders and HIV, Taipei, Taiwan. April 18, 2013
- Instructor. HIV transmission among Injection Drug Users. Research Methods in HIV/AIDS Prevention Course. UCLA School of Public Health. May 14, 2013
- Instructor. HIV/AIDS and Drug Use in the United States. Epidemiology Course. UCLA School of Public Health. May 17, 2013
- Instructor. Measuring Substance Use. Behavioral Epidemiology Course. UCLA School of Public Health. May 20, 2013
- Shoptaw, S. (2013) *Initial outcomes of a Phase 1B, safety interaction trial of Ibudilast as a medication for methamphetamine dependence*. College of Problems on Drug Dependence. Symposium, San Diego, CA. June 18, 2013
- Instructor. Job Skills. International Medical Group Students. UCLA Family Health Center. July 12, 2013
- Shoptaw, S. (2013) *Addiction and dual diagnosis*. National Alliance on Mental Illness' Pathways to Wellness Conference, Los Angeles, CA. July 14, 2013
- Shoptaw, S. (2013) *Multiple Identities and Multiple Health Risks in the LGBT Community*. American Psychological Association Annual Convention, Honolulu, HI. August 4, 2013
- Shoptaw, S. (2013) *Prevention of HIV Transmission by Blood and Through Treatment of Addiction*. Black AIDS Institute HIV Science & Treatment College, Los Angeles, CA. August 26, 2013

August 26th.

- Shoptaw, S. (2013) *People Using Psychoactive Drugs and HIV*. Black AIDS Institute HIV Science & Treatment College, Los Angeles, CA. August 29th. August 29, 2013
- Shoptaw, S. (2013) *Medications for Stimulant Abuse*. California Society of Addiction Medicine Annual Conference. San Diego, CA. October 19th. October 19, 2013
- Shoptaw, S. (2013) *Essential components of HIV Prevention for substance users*. HIV Prevention Trials Network, Webinar, October 23rd. October 23, 2013
- Shoptaw, S. (2013) *The Psychobiology of HIV, Substance Abuse, and Stress*. UCLA HIV/AIDS, Substance Abuse and Trauma Training Program (HA-STTP). Los Angeles, CA. November 18th. November 18, 2013
- Shoptaw, S. (2013) *Managing HIV in Substance Use*. 11th Annual HIV CME Symposium: Tough Decisions Made Easier: Clinical Management of Treatment-Experienced Patients. Los Angeles, CA. November 21. November 21, 2013
- Shoptaw, S., Gorbach, P. (2013) *MASCULINE Cohort Study*. UCLA CHIPTS Community Advisory Board. Los Angeles, CA. December 13. December 13, 2013
- Instructor. Evidence-Based Interventions: Substance Abuse & Dependence. Venice Family Clinic. January 15, 2014
- Instructor. Smoking Cessation. Department of Computer Science, Wireless Health. February 10, 2014
- Instructor. Addiction and Behavioral Medicine in Primary Care. Mental Health Services and Mental Health Policy Course. UCLA. February 7, 2014
- Shoptaw, S., Gorbach, P. (2014) *MASCULINE Cohort Study*. Weekly Cross Disciplinary Conference, UCLA CFAR. Los Angeles, CA. February 18. February 18, 2014
- Shoptaw, S., Gorbach, P. (2014) *MASCULINE Cohort Study*. UCLA CARE Center Community Advisory Board. Los Angeles, CA. February 18. February 18, 2014
- Shoptaw, S. (2014) *Biomedical Interventions in HIV*. Black Treatment Advocates Network: HIV Science and Treatment: An Introduction. Black AIDS Institute. Los Angeles, CA. February 28. February 28, 2014
- Shoptaw, S. (2014) *Smoking Cessation*. WANDA Workshop. UCLA Wireless Health Institute. Los Angeles, CA. March 18. March 18, 2014
- Shoptaw, S., Gorbach, P., Anton, P. (2014) *Immune activation measures in GALT in ART naïve active methamphetamine-using HIV-positive MSM. Symposium #4: Drug Abuse, Neuroimmunology and HIV/AIDS: Perspectives from Addiction Neuropharmacologists*. March 28, 2014



- Society on NeuroImmune Pharmacology 20th Annual Scientific Conference. New Orleans, LA. March 28.
- Shoptaw, S. (2014) *How to Address Structural Factors That Affect Substance Users with HIV*. HPTN Scholars Conference Call. April 17, 2014
- Instructor. Job Skills. International Medical Group Students. UCLA Department of Family Medicine. April 18, 2014
- Shoptaw, S. (2014) *Substance Use Assessment*. Epidemiology Course. University of California, Los Angeles. May 5, 2014
- Shoptaw, S. (2014). *Linkages for High Risk Negatives*. UCLA African American HIV University Science and Treatment College. Los Angeles, CA. May 20, 2014
- Shoptaw, S. (2014) *Drug Use in the USA*. Epidemiology Course. University of California, Los Angeles. May 30, 2014
- Shoptaw, S. (2014) *Discussant: Novel approaches to examining the intertwining epidemics of HIV and drug abuse: Summary and future directions*. College of Problems on Drug Dependence. San Juan, Puerto Rico. June 16, 2014
- Shoptaw, S. (2014) *PrEP Adherence in Black MSM in HPTN073—and Beyond*. CHIPTS Community Forum. Los Angeles, CA. June 24, 2014
- Instructor, Job Skills. International Medical Group Students. UCLA Department of Family Medicine. July 25, 2014
- Instructor, Contingency Management. St John's Well Child & Family Center. August 6, 2014
- Shoptaw, S. (2014) *HIV and Substance Use*. South American Program in HIV/STI Prevention Research Summer Intensive Course. Los Angeles, CA. August 15, 2014
- Shoptaw, S. (2014) *Prevention of HIV Transmission by Blood and Through Treatment of Addiction*. Black AIDS Institute African American HIV University. Los Angeles, CA. September 5, 2014
- Shoptaw, S. (2014) *People Using Psychoactive Drugs and HIV*. Black AIDS Institute African American HIV University. Los Angeles, CA. September 5, 2014
- Instructor. Substance Abuse 101 and Measurement of Substance Use Disorders in the Contexts of Research and Clinical Work. Psychology Intern Seminar. UCLA Semel Institute for Neuroscience and Human Behavior. October 10, 2014
- Instructor. Behavioral economics and recovery from stimulant use disorder. UCLA Addiction Medicine Clinic. November 20, 2014

- Shoptaw, S. (2014) *Safety and Early Efficacy of Ibudilast as a Pharmacotherapy for Methamphetamine Addiction*. American College of Neuropsychopharmacology (ACNP) 53rd Annual Meeting. Phoenix, AZ. December 11, 2014
- Shoptaw, S., Mayer, K., Strathdee, SA. (2015) *Interventions for Stimulant Using MSM*. HIV Prevention Trials Network, PI Webinar, January 14, 2015
- Instructor. Contingency Management, Stimulant Misuse and HIV: New Directions. Harbor-UCLA Medical Center Grand Rounds. January 20, 2015
- Instructor. Evidence-Based Interventions: Substance Abuse & Dependence. Venice Family Clinic. January 21, 2015
- Shoptaw S., Kussin JR. (2015) *Celebrating Parenting: Finding Joy Among the Challenges*. Ventura County Office of Education. Camarillo, CA. March 13, 2015
- Instructor. Contingency Management, Stimulant Misuse and HIV: New Directions. The University of Birmingham at Alabama Psychiatry Grand Rounds. March 24, 2015
- Shoptaw, S. (2015) *Managing Patients with Substance Abuse*. American Conference for the Treatment of HIV (ACTHIV). Dallas, TX. May 2, 2015
- Instructor. Measurement of Substance Use. Epidemiology Course. UCLA School of Public Health. May 4, 2015
- Shoptaw, S. (2015) *Initiating Behavioral Health Conversations with MSM/Gay/Bisexual Men in Primary Care*. LA Care's LGBTQ Health Conference. Los Angeles, CA. May 16, 2015
- Shoptaw, S. (2015) *Non-Injection Drug Use*. HIV Prevention Trials Network Annual Meeting. Arlington, VA. June 16, 2015
- Shoptaw, S. (2015) *Substance Use & HIV*. South American Program in HIV Prevention Research. Los Angeles, CA. August 14, 2015
- Shoptaw, S. (2015) *People Using Psychoactive Drugs and HIV*. Science and Treatment College for the African American HIV University. Los Angeles, CA. August 25, 2015
- Shoptaw, S. (2015) *Prevention of HIV Transmission by Blood and Through Treatment of Addiction*. Science and Treatment College for African American HIV University. Los Angeles, CA. August 25, 2015
- Shoptaw, S. (2015) *Substance Use Seminar*. PSY236 - Psychology Intern Seminar. Los Angeles, CA. October 16, 2015
- Shoptaw, S. (2015) *Using Incentives for Behavior Change*. Division of General Internal Medicine and Health Services Research of the UCLA Department of Medicine. Los Angeles, CA. October 23, 2015

- Shoptaw, S. (2015) *Hitching the Behavioral Science Wagon to the Biomedical HIV Prevention Star*. UCLA HIV/AIDS, Substance Abuse and Trauma Training Program. Los Angeles, CA. November 5. November 5, 2015
- Shoptaw, S. (2015) *Substance Abuse in the Context of HIV: Treatment & Prevention Strategies*. Tough Decisions Made Easier: Clinical Management of Treatment-Experienced Patients. Los Angeles, CA. November 6. November 6, 2015
- Shoptaw, S. (2015) *Methamphetamine Use, Mental Health, and HIV*. University of Washington's AIDS Clinical Conference. Seattle, WA. November 17. November 17, 2015
- Shoptaw, S. (2015) *Non-Injection Drug Use and HIV Infection: New Directions for Behavioral Science*. Center for AIDS Research, University of Washington. Seattle, WA. November 17. November 17, 2015
- Shoptaw, S. (2016) *Overview of Injection Drug Use & HIV/AIDS on a National and International Context*. CHS294 – Social and Behavioral Factors of HIV/AIDS: Global Perspective. Los Angeles, CA. January 26. January 26, 2016
- Shoptaw, S. (2016) *Behavioral Economics, Contingency Management, and Stimulant Misuse: New Directions*. ICLA Integrative Center on Addictions Seminar Series. Los Angeles, CA. January 28. January 28, 2016
- Shoptaw, S. (2016) *State of the Science & Challenges with Self-Report*. UCLA CFAR-Sponsored Substance Use Meeting. Los Angeles, CA. February 1. February 1, 2016
- Shoptaw, S. (2016) *Substance Abuse & Treatment Options*. Venice Family Clinic Mental Health Student Seminar. Los Angeles, CA. February 17. February 17, 2016
- Shoptaw, S. (2016) *Behavioral Economics, Contingency Management, and Stimulant Misuse: New Directions*. UCLA Addiction Medicine Clinic. Los Angeles, CA. March 3. March 3, 2016
- Shoptaw, S. (2016) *Antiretroviral Therapy and Drug Use: Opiate and Stimulants*. United Nations Office on Drugs and Crime, Scientific Consultation, "Science Addressing Drugs & HIV: State of the Art – An Update." Vienna, Austria. March 10. March 10, 2016
- Shoptaw, S. (2016) *Finishing well: Consultations in style and statistics in presenting research*. UCLA Residency Program. Santa Monica, CA. March 16. March 16, 2016
- Shoptaw, S. (2016) *Substance Use Measurement*. EPI 270 – Behavioral Epidemiology. Los Angeles, CA. May 2. May 2, 2016
- Shoptaw, S. (2016) *Using Incentives for Behavior Change*. Academic Day for UCLA Center for East West Medicine. Santa Monica, CA. May 5. May 5, 2016
- Shoptaw, S. (2016) *Managing the Active Meth Users*. Substance Use Tele-Health Sessions. June 23, 2016

- Pacific AIDS Education & Training Center. June 23. Online. August 17, 2016
- Shoptaw, S. (2016). *HIV & Substance Use*. South American Program in HIV Prevention Research Summer Course. Los Angeles, CA. August 17. August 17, 2016
- Shoptaw, S. (2016) *Use of Amphetamine-Type Stimulants and the Risk of HIV Infection in the United States*. ATS Workshop. Hanoi, Vietnam. December 20. December 20, 2016
- Shoptaw, S. (2017). *Treatment and Prevention Approaches for Substance Users at Risk for HIV*. T32 (Hser) Cohort. Santa Monica, CA. January 24. January 24, 2017
- Shoptaw, S. (2017). *Behavioral Health: The Place for Psychology in Treating Addictions in Primary Care*. Behavioral Health & Integrated Care Conference. Alhambra, CA. March 4. March 4, 2017
- Shoptaw, S. (2017). *Odds Ratios and Their Use*. International Medical Graduate Program. Santa Monica, CA. March 24. March 24, 2017
- Shoptaw, S. (2017). *Using Research to Understand Health: Framing Answerable Questions*. UCLA Family Medicine Grand Rounds. Santa Monica, CA. March 29. March 29, 2017
- Shoptaw, S. (2017). *HIV/AIDS and Drug Use in the United States: A Domestic Agenda*. *Epidemiology 277*. Los Angeles, CA. May 26. May 26, 2017
- Shoptaw, S. (2017). *Trends and Technological Approaches to Addressing HIV in Substance Users*. American Psychological Association Annual Conference. Washington, DC. August 5. August 5, 2017
- Shoptaw, S. (2017). *HIV & Alcohol*. South American Program in HIV Prevention Research. Los Angeles, CA. August 8. August 8, 2017
- Shoptaw, S. (2017). *HIV Transmission Dynamics and Substance Use: New Findings from M-Study*. UCLA CARE Prevention Community Advisory Board. Los Angeles, CA. August 16. August 16, 2017
- Shoptaw, S. (2017). *HIV & Substance Use*. South American Program in HIV Prevention Research. Los Angeles, CA. August 17. August 17, 2017
- Shoptaw, S. (2017). *Behavioral Interventions for Substance Abuse in the Setting of HIV*. Fogarty International Center, Vietnam. Hanoi, Vietnam. September 6, 2017. September 6, 2017
- Shoptaw, S. (2017). *Medications for Substance Use Disorder in the Setting of HIV*. Fogarty International Center, Vietnam. Hanoi, Vietnam,. September 7. September 7, 2017
- Shoptaw, S. (2017). *Substance Use Disorder*. UCLA Clinical Psychology Doctoral Intern Seminar. Los Angeles, CA. September 15. September 15, 2017
- Shoptaw, S. (2017). *Translating Evidence-Based Psychosocial Into Structured Treatment* October 20,

- Protocols*. United Nations Office on Drugs and Crime. Vienna, Austria. October 20. 2017
- Shoptaw, S. & Goodman-Meza, D. (2017). *Scientific and Clinical Perspectives on Cannabis Use: A Q&A Puff Through the Literature*. Integrated Care Conference. Universal City, CA. October 25, 2017
- Goodman-Meza, D. & Shoptaw, S. (2018) *Scientific and Clinical Perspectives on Cannabis Use*. Ventura County Interagency Marijuana Workgroup Seminar. January 10. 2018
- Shoptaw, S. (2018). *ACTG and HPTN Trial Findings in PLHIV with Low Adherence: Implications for CTN HIV Research Agenda*. Clinical Trials Network Meeting. Austin, Texas. March 22. 2018
- Shoptaw, S. (2018). *Psychometric Aspects of Assessment of Alcohol and Drug Use*. UCLA Department of Epidemiology, Epidemiology 227. Los Angeles, CA. May 2. 2018
- Shoptaw, S. (2018). *HIV and Substance Use*. South American Program in HIV/STI Prevention Research Summer Intensive Course. Los Angeles, CA. August 6. 2018
- Shoptaw, S. (2018). *HIV and Alcohol*. South American Program in HIV/STI Prevention Research Summer Intensive Course. Los Angeles, CA. August 7. 2018
- Fitzpatrick, O.M., Bai, S., Zeledon, L.R., D'Amico, E., LaBorde, A., Anderson, M., Avina, C., Shoptaw, S., & Asarnow, J.R. (2018, November). *Reducing health risk behaviors and depression in adolescents: A randomized controlled trial in primary care clinics*. The Association for Behavioral and Cognitive Therapies Annual Conference (52nd). Washington D.C. 2018
- Passaro, C.R., Segura, E.R., Lake, J.E., Reback, C.J., Clark, J.L., Shoptaw, S. (2018). *Speed Kills: Associations between methamphetamine use, HIV infection, tobacco use, and accelerated mortality among gay and bisexual men in Los Angeles, CA 20 years after methamphetamine dependence treatment*. UCLA Center for AIDS Research Grand Rounds. Los Angeles, CA. December 4. 2018
- Shoptaw, S. (2018). *Substance Use and Mental Health Research in HIV Prevention: If Past is Prologue...* UCLA Psychiatry Residents Research Seminar. Los Angeles, CA. December 19. 2018
- Shoptaw, S. (2019). *Methamphetamine Use and HIV Relevant Outcomes in MSM in Los Angeles: Biological and Behavioral Links*. HIV Center for Clinical and Behavioral Studies, Columbia University. New York, NY. February 21. 2019
- Shoptaw, S., Javanbakht, M., Ragsdale, A., Bolan, B., Gorbach, P.M. (2019) *Methamphetamine Dose, Clinical Outcomes, and HIV Status Links Among Diverse MSM in LA*. Poster Presented at the Conference on Retroviruses and Opportunistic Infections 2019. Seattle, WA. March 4. 2019
- March 4, 2019

- Fulcher, J.A., Javanbakht, M., Shover, C.L., Ragsdale, A., Brookmeyer, R., Shoptaw, S., Gorbach, P.M. (2019). Attributable Risk Of Methamphetamine Use on Viral Suppression Among MSM on ART. Poster Presented at the Conference on Retroviruses and Opportunistic Infections 2019. Seattle, WA. March 4.
- Shoptaw, S. (2019). *Mechanisms of Contingency Management Treatment for Methamphetamine Addiction in Cape Town, South Africa*, UCLA Department of Psychiatry Grand Rounds. Los Angeles, CA. April 16. April 16, 2019
- Shoptaw, S. (2019). *Substance Use Measurement*. EPI270 – Behavioral Epidemiology. Los Angeles, CA. May 6. May 6, 2019
- Shoptaw, S. (2019). *Managing Patients with Substance Use*. OSD203 – Oral & Systemic Diseases III. Los Angeles, CA. May 20. May 20, 2019
- Shoptaw, S. (2019). *HIV/AIDS and Drug Use in the United States: A Domestic Agenda*. EPI227 – AIDS: Major Public Health Challenge. Los Angeles, CA. May 31. May 31, 2019
- Shoptaw, S. (2019). *Addressing the Effects of Non-Injection Substance Use on HIV Viral Load*. HIV Prevention Trials Network Annual Meeting 2019. Washington, DC. June 1, 2019.
- Shoptaw, S. (2019). *Sexualized Drug Use: Global Trends and the Effect on the HIV Epidemic*. HIV Prevention Trials Network Annual Meeting 2019. Washington, DC. June 4. June 4, 2019
- Shoptaw, S. (2019). *Mental Health, Substance Use, and HIV: Calming the “Perfect Storm.”* Adherence 2019. Miami Beach, FL. June 19. June 19, 2019
- Shoptaw, S. (2019). *The Impact of Mental Health and Substance Use Disorder on Reaching Global HIV Care and Prevention Targets*. 10<sup>th</sup> International AIDS Society Conference on HIV Science. Mexico City, Mex. July 24. July 24, 2019
- Shoptaw, S. (2019). *Stimulant Use & HIV: The Crisis Continues*. Mountain West AIDS Education and Training Center AIDS Clinical Conference. Seattle, WA. October 15. October 15, 2019
- Shoptaw, S. (2019). *Stimulant Use Disorder: 25 Years and the Crisis Continues*, Australasian Professional Society on Alcohol & other Drugs 2019 Conference. Hobart, Australia. November 11, 2019
- Shoptaw, S. (2019). *Update on Substance Misuse in HIV Settings*. 17<sup>th</sup> Annual HIV CME Symposium. Los, Angeles, CA. December 17. December 17, 2019
- Shoptaw, S. (2020). *Methamphetamine and HIV: The Next Decade of HIV Prevention*. UCSF Center for AIDS Research Seminar. San Francisco, CA. January 15, 2020
- Shoptaw, S. (2020). *Treatment of Opioid Use Disorder*. Pacific AIDS Education and Training Center at USC VIRTUAL lecture. May 7. May 7, 2020

- Shoptaw, S. (2020). *Assessing Substance Use*. EPI270 – Behavioral Epidemiology. VIRTUAL lecture. May 11. May 11, 2020
- Shoptaw, S. (2020). *Contingency Management: Mechanisms of Action*. UCLA Translational Neuroscience Drug Abuse (TNDA) VIRTUAL retreat. May 20. May 20, 2020
- Shoptaw, S. (2020). *CHIPTS 101*. UCLA Government Offices VIRTUAL Presentation. June 26. June 26, 2020
- Shoptaw, S. (2020). *Syndemics of Drug Use, HIV, HCV: An Integrated Approach in Primary Care*. AIDS 2020 VIRTUAL Conference. July 8. July 8, 2020
- Shoptaw, S. (2020). *Methamphetamine Use and HIV in MSM in Los Angeles: Biology and Behavior*. The Wall Las Memorias (TWLM) Act Now Against Meth Campaign VIRTUAL Town Hall Briefing. July 21. July 21, 2020
- Shoptaw, S. (2020). *CHIPTS Scientific Advisory Board Meeting*. CHIPTS Cross Core HIV VIRTUAL Commission Panel. August 21. August 21, 2020
- Shoptaw, S. (2020). *Managing Patients with Substance Abuse*. OSD201 – Oral & Systemic Diseases I. VIRTUAL lecture. September 29. September 29, 2020
- Shoptaw, S. (2020). *Designing and Implementing Randomized Clinical Trials (RCTs) in Drug Addiction Research*. Charles R. Drew University Substance Abuse Research Training Program (START) Institute 1: Methodological Skills Development VIRTUAL Training. October 16. October 16, 2020
- Shoptaw, S. (2020). *Stimulant Use Disorder: 25 Years and the Crisis Continues*. AIDS Healthcare Foundation Grand Rounds. VIRTUAL. October 21. October 21, 2020
- Brown A, Matthews D, Meanley S, Haberlen S, D'Souza G, Ware D, Egan JE, Brennan-Ing M, **Shoptaw S**, Teplin L, Friedman MR. *Resilience, discrimination, and depressive symptoms among aging men who have sex with men*. In APHA's 2020 VIRTUAL Annual Meeting and Expo (Oct. 24-28) 2020 Oct 28. American Public Health Association. October 28, 2020
- Shoptaw, S. (2020). *Screen, Treat and Retain Meth-Using People with Opioid Use Disorders at MMT Clinics (STAR-OM)*. Center for Training and Research on Substance Abuse-HIV at Hanoi Medical University VIRTUAL Seminar. October 28. October 28, 2020
- Shoptaw, S. (2020). *Treatments for Stimulant Use Disorder*. Vietnam Ministry of Health and Center for Training and Research on Substance Abuse-HIV at Hanoi Medical University VIRTUAL Seminar. October 29. October 29, 2020
- Shoptaw, S. (2020). *Motivational Interviewing for CMAX*. UVSC VIRTUAL Discussion. November 6. November 6, 2020
- November 9,

- Shoptaw, S. (2020). *Mentorship and Career Metrics Keeping Your Wagon Hitched to a Star*. Rotheram-Borus T32 Postdoctoral Fellows VIRTUAL Group Meeting. November 9. 2020
- Shoptaw, S. (2020). *Substance Use and Misuse in HIV*. South American Program in HIV Prevention Research (SAPHIR) VIRTUAL Lecture. November 19. November 19, 2020
- Shoptaw, S. (2020). *Continuing Mentorship After the Scholar's Program*. The HIV Prevention Trials Network Scholars Program VIRTUAL Lecture. November 19. November 19, 2020
- Shoptaw, S. (2020). *Methamphetamine Use: What We Need to Know; What We Need to Do*. AIDS Project Los Angeles (APLA) VIRTUAL lecture. December 7. December 7, 2020
- Shoptaw, S. (2020). *Update on Methamphetamine Use*. Act Now Against Meth (ANAM) 2<sup>nd</sup> VIRTUAL Roundtable. December 9. December 9, 2020



Steven J. Shoptaw, Ph.D.  
Bibliography

**PUBLICATION/BIBLIOGRAPHY:**

**RESEARCH PAPERS**

RESEARCH PAPERS (PEER REVIEWED)

**A. Research Papers- Peer Reviewed**

1. Taylor, S.E., Falke, R.L., **Shoptaw, S.J.**, Lichtman, R.R. Social support, support groups, and the cancer patient. *Journal of Consulting and Clinical Psychology*. 1986; 54(5), 608-615.
2. Rawson, R., **Shoptaw, S.**, Simmonds, J. Chemical dependency treatment and HIV disease: A challenge for the addictions field. *Addiction & Recovery*. 1993; 13(1), 13-15.
3. **Shoptaw, S.**, Rawson, R.A., McCann, M.J., Obert, J.L. The Matrix model of outpatient stimulant abuse treatment: Evidence of efficacy. *Journal of Addictive Diseases*. 1994; 13(4), 129-141.
4. Rawson, R., **Shoptaw, S.**, Obert, J.L., McCann, M.J., Hasson, A.L., Marinelli-Casey, P.J., Brethen, P.R., Ling, W. An intensive outpatient approach for cocaine abuse treatment: The Matrix Model. *Journal of Substance Abuse Treatment*. 1995; 12 (2), 117-127.
5. **Shoptaw, S.**, Rawson, R.A., McCann, M.J., and Obert, J.L. The Matrix model of outpatient stimulant abuse treatment: Evidence of efficacy. In Magura, S. and Rosenblum, A. (Eds), *Experimental Therapeutics*. 1995; 129-141.
6. **Shoptaw, S.**, Jarvik, M.E., Ling, W., Rawson, R.A. Contingency management for tobacco smoking in methadone maintained opiate addicts. *Addictive Behaviors*. 1996; 21(3), 409-412.
7. Frosch, D., **Shoptaw, S.**, Huber, A., Rawson, R.A., Ling, W. Sexual HIV risk among gay and bisexual male methamphetamine abusers. *Journal of Substance Abuse Treatment*. 1997; 13(6), 483-486.
8. Huber, A., Ling, W., **Shoptaw, S.**, Gulati, V., Brethan, P., Rawson, R.A. Integrating treatments for methamphetamine abuse: A psychosocial perspective. *Journal of Addictive Diseases*. 1997; 16(4), 41-50.
9. Ling, W., **Shoptaw, S.** Integration of research in pharmacotherapy for addictive disease: Where are we? Where are we going? *Journal of Addictive Diseases*. 1997; 16(4), 83-102.
10. McCann, M.J., Miotto, K., Rawson, R.A., Huber, A., **Shoptaw, S.**, Ling, W. Outpatient non-opioid detoxification for opioid withdrawal: Who is likely to benefit? *The American Journal of the Addictions*. 1997; 6(3), 218-223.
11. **Shoptaw, S.**, Frosch, D., Rawson, R.A., Ling, W. Cocaine abuse counseling as HIV prevention.

*AIDS Education and Prevention*. 1997; 9(6), 511-520.

12. Frosch, D., **Shoptaw, S.**, Jarvik, M.E., Rawson, R.A., Ling, W. Interest in smoking cessation among methadone maintained outpatients. *Journal of Addictive Diseases*. 1998; 17(2), 9-19.
13. Ling, W., **Shoptaw, S.**, Majewska, D. Baclofen as a cocaine anti-craving medication: A preliminary clinical study. *Neuropsychopharmacology*. 1998; 18(5), 403-404.
14. **Shoptaw, S.**, Reback C.J., Frosch, D.L., Rawson, R.A. Stimulant abuse treatment as HIV prevention. *Journal of Addictive Diseases*. 1998; 17(4), 19-32.
15. **Shoptaw, S.**, Reback C.J., Frosch, D.L., & Rawson, R.A. Stimulant abuse treatment as HIV prevention. Co-occurring in E.Gottheil and B.Stimmel (eds.), *Effects of Substance Abuse Treatment on AIDS Risk Behavior*. *Haworth Medical Press*: 1998; 19-32.
16. Frosch, D., **Shoptaw, S.**, Nahom, D., & Jarvik, M.E. Associations between tobacco smoking and illicit drug use among methadone maintained opiate-dependent individuals. *Experimental & Clinical Psychopharmacology*. 2000; 8(1), 1-7.
17. Kirkish, P., Sreenivasan, S., Welsh, R., Van Gorp, W., Eth, S., **Shoptaw, S.**, & Ling, W. The future of criminal violence: Juveniles tried as adults. *Journal of the American Academy of Psychiatry and the Law*. 2000; 28(1), 38-46.
18. Rawson, R., Huber, A., Brethen, P., Obert, J., Gulati, V., **Shoptaw, S.**, Ling, W. Methamphetamine and cocaine users: Differences in characteristics and treatment retention. *Journal of Psychoactive Drugs*. 2000; 32(2), 233-238.
19. **Shoptaw, S.**, Frosch, D. Substance abuse treatment as HIV prevention for men who have sex with men. *AIDS & Behavior*. 2000; 4(2), 193-203.
20. **Shoptaw, S.**, Stein, J.A., Rawson, R.A. Burnout in substance abuse counselors: Impact of environment, attitudes, and clients with HIV. *Journal of Substance Abuse Treatment*. 2000; 19(2), 117-126.
21. Sreenivasan, S., Kirkish, P., **Shoptaw, S.**, Welsh, R.K., Ling, W. Neuropsychological and diagnostic differences between recidivistically violent not criminally responsible and mentally ill prisoners. *International Journal of Law and Psychiatry*. 2000; 23(2), 161-172
22. Rawson, R.A., McCann, M.J., **Shoptaw, S.**, Miotto, K.A., Frosch, D.L., Obert, J.L., Ling, W. Naltrexone for opioid dependence: Evaluation of a manualized psychosocial protocol to enhance treatment response. *Drug & Alcohol Review*. 2001; 20, 67-78.
23. Frosch, D.L., Nahom, D., **Shoptaw, S.** Optimizing smoking cessation outcomes among the methadone maintained. *Journal of Substance Abuse Treatment*. 2002; 23, 425-430.
24. Frosch, D.L., Stein, J.A., **Shoptaw, S.** Using latent-variable models to analyze smoking cessation clinical trial data: An example among the methadone maintained. *Experimental & Clinical Psychopharmacology*. 2002; 10(3), 258-267.

25. Rawson, R.A., Huber, A., Brethen, P., Obert, J., Gulati, V., **Shoptaw, S.**, Ling, W. Status of methamphetamine users 2-5 years after outpatient treatment. *Journal of Addictive Diseases*. 2002; 21 (1), 107-119.
26. Rawson, R.A., Huber, A., McCann, M., **Shoptaw, S.**, Farabee, D., Reiber, C., Ling, W. A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. *Archives of General Psychiatry*. 2002; 59, 817-824.
27. Reback, C.J., Cohen, A.J., Freese, T.E., **Shoptaw, S.** Making collaboration work: Key components of practice/research partnerships. *Journal of Drug Issues*. 2002; 32(3), 837-848.
28. **Shoptaw, S.**, Kintaudi, P.C., Charuvastra, C., Ling, W. A screening trial of amantadine as a medication for cocaine dependence. *Drug & Alcohol Dependence*. 2002; 66(3), 217-224.
29. **Shoptaw, S.**, Reback C.J., Freese, and T.E. Patient characteristics, HIV serostatus, and risk behaviors among gay and bisexual males seeking treatment for methamphetamine abuse and dependence in Los Angeles. *Journal of Addictive Diseases*. 2002; 21(1), 91-105.
30. **Shoptaw, S.**, Rotheram-Fuller, E., Yang, X., Frosch, D., Nahom, D., Jarvik, M.E., Rawson, R.A., Ling, W. Smoking cessation in methadone maintenance. *Addiction*. 2002; 97(10), 1317-1328.
31. Twitchell, G., Huber, A., Reback, C., **Shoptaw, S.** Comparison of general and detailed HIV risk assessments among methamphetamine abusers. *AIDS & Behavior*. 2002; 6(2), 153-162.
32. Reback, C.J., Larkins, S., **Shoptaw, S.** Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. *AIDS Care*. 2003; 15(6), 775-785.
33. **Shoptaw, S.**, Yang, X., Rotheram-Fuller, E.J., Hsieh, Y.C., Kintaudi, P.C., Charuvastra, V.C., Ling, W. Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. *Journal of Clinical Psychiatry*. 2003; 64(12): 1440-1448.
34. Covey, L.S., Joseph, A.M., **Shoptaw, S.** Response: Getting tough with smoking. *NIDA Science & Practice Perspectives*. 2003; July, 40-43.
35. Covey, L.S., Joseph, A.M., **Shoptaw, S.** Response: Getting tough with smoking. *Science and Practice Perspectives*. 2003; Aug; 2(1):40-2. No abstract available. PMID: 18552721
36. **Shoptaw, S.**, Peck, J., Reback, C.J., Rotheram-Fuller, E. Psychiatric and substance dependence co-morbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment. *Journal of Psychoactive Drugs*. 2003; 35 (Suppl 1), 161-168.
37. Kranzler, H.R., Wesson, D.R., Billot, L., (Drug Abuse Sciences Naltrexone Depot Study Group), **Shoptaw, S.** Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. *Alcoholism: Clinical and Experimental Research*. 2004; 28 (7): 1051-1059.

38. **Shoptaw, S.**, Majewska, M.D., Wilkins, J., Twitchell, G., Ling, W. Participant receiving DHEA during treatment for cocaine dependence show high rates of cocaine use in a placebo – controlled pilot study. *Experimental and Clinical Psychopharmacology* 2004; 12: 126-135.
39. Reback, C.J., Larkins, S., **Shoptaw, S.** Changes in the meaning of sexual risk behaviors among gay and bisexual male methamphetamine abusers before and after drug treatment. *AIDS Behavior* 2004; 8(1), 87-98.
40. Rotheram-Fuller, E., **Shoptaw, S.**, Berman, S.M., London, E.D. Impaired performance in a test of decision-making by opiate-dependent tobacco smokers. *Drug & Alcohol Dependence*. 2004; 73(1):79-86.
41. Scott, R.L., **Shoptaw, S.** A pilot study of contextual and partner factors that contribute to unprotected sex across African American sexual identities. *The Community Psychologist*. 2004; 36(4) 9-11.
42. Rawson, R., McCann, M., Flammino, F., **Shoptaw, S.**, Miotto, K., Reiber, C., Ling, W. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. *Addiction*. 2005; Feb 101(2):267-74
43. Kanouse, D.E., Bluthenthal, R.N., Bogart, L., Iguchi, M.Y., Perry, S., Sand, K., **Shoptaw, S.** Recruiting drug-using men who have sex with men into behavioral interventions: A two-stage approach. *Journal of Urban Health*. 2005; Mar; 82 (1 Suppl 1):i109-19.
44. **Shoptaw, S.**, Reback, C.J., Peck, J.A., Yang, X., Rotheram-Fuller, E., Larkins, S., Veniegas, R.C., & Hucks-Ortiz, C. (2005). Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. *Drug & Alcohol Dependence*. 2005; 78(2) May: 125-134.
45. Nyamathi, A.M., Christiani, A., Windoku, F., Jones, T., Strehlow, A., **Shoptaw, S.** Hepatitis C virus infection, substance use and mental illness among homeless youth. *Journal of Acquired Immune Deficiency Syndrome*. 2005; Oct; 19 Suppl 3:S34-40.
46. Colfax, G., **Shoptaw, S.** The methamphetamine epidemic: implications for HIV prevention and treatment. *Current HIV/AIDS Report*. 2005; Nov; 2 (4):194-9.
47. Campos, M., **Shoptaw, S.**, Evidence-based treatments for methamphetamine abuse. *Focus: A Guide to AIDS Research and Counseling*. 2005; 20 (6) 5-8.
48. Peck, J.A., **Shoptaw, S.**, Rotheram-Fuller, E., Reback, C.J., Bierman, B. HIV-associated medical, behavioral, and psychiatric characteristics among methamphetamine-dependent treatment-seeking gay and bisexual men. *Journal of Addictive Diseases*. 2005; 24: 115-132.
49. Ling, W., Amass, L., **Shoptaw, S.**, Annon, J.J., Babcock, D., Brigham, G., Harrer, J., Reid, M., Muri, J., Buchan, B., Orr, D., Woody, G., Krejcija, J., Ziedonis, D., and the Buprenorphine Study Protocol Group. A multi-center randomized trial of Buprenorphine-naloxone and clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. *Addiction*. 2005; 100:1090-1100. PMID: PMC1480367

50. Larkins, S., Reback, C.J., **Shoptaw, S.**, Veniegas, R. Methamphetamine-dependent gay men's disclosure of their HIV status to sexual partners. *AIDS Care*. 2005; 17:521-532.
51. 51. Elkashef, A., Holmes, T.H., Bloch, D.A., **Shoptaw, S.**, Kampman, K., Reid, M., Somoza, E., Ciraulo, D., Rotrosen, J., Leiderman, D., Montgomery, A., & Vocci, F. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. *Addiction*. 100 (Supplement 1) 2005; 91-101.
52. Leiderman, D.B., **Shoptaw, S.**, Montgomery, A., Bloch, D.A., Elkashef, A., LoCastro, J., & Vocci, F. Cocaine rapid efficacy screening trial (CREST): A paradigm for the controlled evaluation of candidate medications for cocaine dependence, *Addiction*. 100 (Supplement 1): 2005; 1-11.
53. Kampman, K.M., Leiderman D, Holmes T, LoCastro J, Bloch DA, Reid MS, **Shoptaw S**, Montgomery MA, Winhusen TM, Somoza EC, Ciraulo DA, Elkashef A, & Vocci F. Cocaine rapid efficacy screening trials (CREST): Lessons learned, *Addiction*. 100 (Supplement 1): 2005; 102-110.
54. Peck, J.A., Reback, C.J., Yang, X., Rotheram-Fuller, E., **Shoptaw, S.** Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. *Journal of Urban Health*. 2005; 82 (1Suppl 1): i100-i108.
55. **Shoptaw, S.**, Watson, D.W., Reiber, C., Rawson, R.A., Montgomery, A., Majewska, D., & Ling, W. Randomized controlled trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles cocaine rapid efficacy and safety trial (CREST), *Addiction*. 100(Supplement 1): 2005; 78-90.
56. **Shoptaw, S.** Clinical Rapid Efficacy Screening Trials (CREST; ed. S. Shoptaw). *Addiction*. 100 Supplement 1: 2005; 1-110).
57. Yang, X., **Shoptaw, S.** Assessing missing data assumptions in longitudinal studies: An example using a smoking cessation trial. *Drug & Alcohol Dependence*. 2005; 77(3):213-225.
58. Roll, J. M., Huber, A., Sodano R., Chudzynski, J. E., Moynier, E., & **Shoptaw, S.**, A comparison of five reinforcement schedules for use in contingency management-based treatment of methamphetamine abuse. *Psychological Record*. 2006; Vol. 56, 67-81.
59. 59. Larkins, S., Reback, C.J., **Shoptaw, S.**, HIV risk behaviors among gay male methamphetamine users: Before and after treatment. *Journal of Gay & Lesbian Psychotherapy*. 2006; 10 (3-4), 123-129. DOI: 10.1300/J236v10n03\_11
60. Gonzales, R., Marinelli-Casey, P., **Shoptaw, S.**, Ang, A., Rawson, R. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. *Journal of Substance Abuse Treatment*. 2006; 31 195-202
61. Menza, T.W., Colfax, G., **Shoptaw, S.**, Fleming, M., Guzman, R., Klausner, J.D., Gorbach, P., Golden, M.R. Interest in a methamphetamine intervention among men who have sex with men. *Journal of Sexually Transmitted Disease*. 2006 Apr; 34 (4):209-14.

62. Yang, X., Shen, Q., Xu, H., **Shoptaw, S.** Functional regression analysis using an F test for longitudinal data with large numbers of repeated measures. *Statistics in Medicine*. 2006; June 30.
63. **Shoptaw, S.** Methamphetamine use in urban gay and bisexual populations. *Topics in HIV Medicine*. 2006; Jun-Jul 14(2):84-7.
64. **Shoptaw, S.**, Klausner, J.D, Reback, C.J., Tierney, S., Stansell, J., Hare C.B., Gibson, S., Siever, M., King, W.D., Kao, U., Dang, J. A public health response to the methamphetamine epidemic: The implementation of contingency management to treat methamphetamine dependence. *BMC Public Health*. 2006; Aug 18; 6:214.
65. Roll, J.M. & **Shoptaw, S.**, Contingency management for the treatment of methamphetamine abuse: Schedule effects. *Psychiatry Research*. 2006; Sep 30; 144 (1):91-3.
66. Ling, W., Rawson, R., **Shoptaw, S.** Management of methamphetamine abuse and dependence. *Current Psychiatry Reports*. 2006; October 345-54
67. **Shoptaw, S.**, Huber, A., Peck J.A., Yang, X., Liu, J., Roll, J., Shapiro, B., Rotheram-Fuller, E., Dang, J., Ling, W. Randomized, placebo-controlled trial of Sertraline and contingency management for the treatment of methamphetamine dependence. *Drug & Alcohol Dependence*. 2006; Vol. 85 Issue 1 Oct 15.
68. Strona F., McCright J., Hjord H., Ahrens K., Tierney S., **Shoptaw S.**, Klausner J. The acceptability and feasibility of the Positive Reinforcement Opportunity Project, a community-based contingency management methamphetamine treatment program for gay and bisexual men in San Francisco. *Journal of Psychoactive Drugs*. 2006; Nov; Suppl 3:377-83
69. **Shoptaw, S.**, Reback, C., Associations between Methamphetamine use and HIV among men who have sex with men: A model for guiding public policy. *Journal of Urban Health*. 2006; Nov; 83(6):1151-7
70. Heinzerling, K., **Shoptaw, S.**, Peck, J., Yang, X., Liu, J., Ling, W., Randomized, placebo-controlled trial of Baclofen and Gabapentin for the treatment of methamphetamine dependence. *Drug & Alcohol Dependence*. 2006 Dec 1; 85(3):177-84.
71. Nyamathi, A., McNeese-Smith, D., **Shoptaw, S.**, Mutere, M., Cohen, A., Amrani I., Morales L., Castro V., Perceptions of methadone maintained clients about barriers and facilitators to help-seeking behavior. *Progress in Community Health Partnerships: Research Education and Action*. 2007; 1 (4): 301-310.
72. Goldstein R., Asarnow, J., Jaycox, L., **Shoptaw, S.** Correlates of “nonproblematic” and “problematic” substance use among depressed Adolescents in primary care. *Journal of Addictive Diseases*. 2007; 26(3):39-52.
73. Rotheram-Fuller, E., De La Gaza, R., Mahoney, J., **Shoptaw, S.**, Newton, T., Subjective and cardiovascular effects of cocaine during treatment with Amantadine and Baclofen in combination. *Psychiatry Research*. 2007; Apr 19

74. Li, J., Yang, X., Wu, Y., **Shoptaw, S.** A random-effects Markov transition model for Poisson-distributed repeated measures with non-ignorable missing values. *Statistics in Medicine*. 2007; May 30; 26(12):2519-32.
75. **Shoptaw, S.**, Reback, C., Methamphetamine use and infectious disease related behaviors in men who have sex with men: implications for interventions. *Addiction*. 2007; 102 (Suppl. 1) 130-135.
76. Jaffe, A., **Shoptaw, S.**, Stein, J.A., Reback, C.J., Rotheram-Fuller, E., Depression ratings, reported sexual risk behaviors, and Methamphetamine Use: Latent growth curve models of positive change among gay and bisexual men in an outpatient treatment program. *Experimental and Clinical Psychopharmacology*. 2007; Jun; 15(3):301-7
77. Yang, X., Nie, K., Belin, T.R., Liu, J., **Shoptaw S.** Markov transition models for binary repeated measures with ignorable and non-ignorable missing values. *Statistical Methods in Medical Research*. 2007; Aug; 16 (4):347-64.
78. Nyamathi, A., de Castro, V., McNeese-Smith D., Nyamathi K., **Shoptaw, S.**, Marfisse, M., Khalilifard, F., Cohen, A. Alcohol use reduction program in methadone maintained individuals with HCV infection. *Journal of Addictive Diseases*. 2008; Vol. 27(4) 27-33. PMID: Non Applicable
79. **Shoptaw, S.**, Heinzerling, K., Rotheram-Fuller, E., Kao, U.H., Wang, P.C., Bholat, M.A., & Ling, W. Bupropion hydrochloride vs. placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine Abuse/Dependence. *Journal of Addictive Diseases*. 2008; 27(1):13-23.
80. **Shoptaw, S.**, Rotheram-Fuller, E., Landovitz, R., Wang, J., Moe, A., Reback, C.J., Kanouse, D. (2008). Non-occupational post exposure prophylaxis as a biobehavioral HIV prevention intervention. *AIDS Care*. 20(3): 376-381. PMID: PMC Not Applicable.
81. King, W.D., Larkins, S., Hucks-Ortiz, C., Gorbach, P., Veniegas, R., **Shoptaw, S.**, Factors associated with HIV viral load in A respondent driven sample in Los Angeles. *AIDS & Behavior Journal*. 2008; Feb; 13(1):145-53. PMID: PMC2649661
82. De La Garza, II, R., Mahoney, III, J.J., Culbertson, C., **Shoptaw, S.**, Newton, T.F. The Acetylcholinesterase inhibitor Rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. *Pharmacology Biochemistry & Behavior*. 2008; Apr (2)00-8.
83. Yang, X., Li, J., **Shoptaw, S.** Imputation-based strategies for clinical trial longitudinal data with nonignorable missing values. *Statistics in Medicine*. 2008; Jul 10; 27(15):2826-49 PMID: PMC3032542
84. **Shoptaw, S.**, Heinzerling, K.G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A.N., De La Garza, R., Newton, T., Ling, W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. *Drug & Alcohol Dependence*. 2008; Aug 1; 96 (3):222-32. PMID: PMC3652530

85. King, W.D., Minor P., Ramirez-Kitchen C., Ore, L.E., **Shoptaw, S.**, Victorianne, G.D, Rust G. Racial, Gender & Geographic Disparities of antiretroviral treatment among US Medicaid enrollees in 1998. *Journal of Epidemiology and Community Health*. 2008; Sep. 62 (9),798-803.
86. De La Garza, II, R., **Shoptaw, S.**, Newton, T.F. Evaluation of the cardiovascular and subjective effects of rivastigmine in combination with methamphetamine in methamphetamine-dependent human volunteers. *International Journal of Neuropsychopharmacology*. Sep; 11(6):729-41. PMID: PMC2581751
87. **Shoptaw, S.**, Reback, C.J., Larkins, S., Wang, P, Rotheram-Fuller, E., Dang, J., Yang, X. Outcomes using two tailored behavioral treatments for substance abuse in urban gay and bisexual men. *Journal of Substance Abuse Treatment*. 2008; Oct; 35(3):285-93. PMID: PMC2214821
88. Nyamathi, A., Dixon, E., **Shoptaw, S.**, Marfisee, M., Gelberg, L., Williams, S., Dominick, S., & Leake, B. Profile of lifetime methamphetamine use among homeless adults in Los Angeles. *Drug & Alcohol Dependence*. 2008; 92, 277-281.
89. Reback C., **Shoptaw S.**, Grella C., Methamphetamine use trends among street-recruited gay and bisexual Males, from 1999 to 2007. *Journal of Urban Health*. 2008; Nov; 85(6):874-9. PMID: PMC2587649
90. Nyamathi, A., Compton, P., Cohen, A., Marfisee, M., **Shoptaw, S.**, Greengold, B., Castro, V.D., Reaves, M., Hasson, A, George, D., Leake, B. Correlates of hospitalization for alcohol-using methadone-maintained persons with physical health problems. *Western Journal of Nursing Research*. 2009; 31(4): 525-543. PMID: PMC3806279
91. Rudy, E.T., **Shoptaw, S.**, Lazzar, M., Bolan, R.K., Tilekar, S.D., Kerndt, P.R. Methamphetamine use and other club drug use differ in relation to HIV status and risk behavior among gay and bisexual men. *Sexually Transmitted Disease*. 2009; 36(11):693-695 PMID: PMC3005257
92. Dean, A., London, E., Sugar, C., Kitchen, C., Swanson, A., Heinzerling, K., Kalechstein, A., **Shoptaw, S.** Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. *Drug & Alcohol Dependence*. 2009; 105(1-2): 48-55. PMID: PMC2754143
93. Gorbach, P.M., Murphy, R., Weiss, R.E., Hucks-Ortiz, C., **Shoptaw, S.** Bridging sexual boundaries: Men who have sex with men and women in a street-based sample in Los Angeles. *Journal of Urban Health*. 2009; 86 Suppl 1:63-76. PMID: PMC2705489
94. Iguchi, M.Y., Ober, A.J., Berry, S., Fain, T., Heckathorn, D.D., Gorbach, P.M., Heimer, R., Kozlov, A.P., Ouellet, L.J., **Shoptaw, S.**, Zule, W.A. Simultaneous recruitment of drug users and men who have sex with men in the United States and Russia using respondent driven sampling: Sampling methods and implications. *Journal of Urban Health*. 2009; 86 Suppl 1:5-3. PMID: PMC2705484
95. **Shoptaw, S.**, Weiss, R., Munjas, B., Hucks-Ortiz, C., Larkins, S., Victorianne, G., Gorbach, P. Homonegativity, substance use, sexual risk behaviors and HIV-status in poor and ethnic men



- who have sex with men in Los Angeles. *Journal of Urban Health*. 2009; 86 Suppl 1:77-92. PMID: PMC2705491
96. Nyamathi, A., Liu, E., Marfisee, M., **Shoptaw, S.**, Leake, B., Tyler, D., Gelberg, L. Effects of a nurse-managed program on hepatitis A and B vaccine completion among homeless adults. *Journal of Nursing Research*. 2009; Jan-Feb; 58 (1):13-22. PMID: PMC3076026
  97. De La Garza, R., Zorick, T., Heinzerling, K., Nusinowitz, S., London, E., **Shoptaw, S.**, Moody, D., Newton, T. The cardiovascular and subjective effects of methamphetamine combined with gamma-vinyl-gamma-aminobutyric acid (GVG) in non-treatment seeking methamphetamine-dependent volunteers. *Pharmacology, Biochemistry & Behavior*. 2009; 94(1):186-193. PMID: PMC2775447
  98. **Shoptaw, S.J.**, Kao, U., Ling, W.W. Treatment for amphetamine psychosis. *Cochrane Database of Systemic Reviews*. 2009; (1):CD003026. PMID: PMC Not Applicable
  99. Nyamathi, A., Cohen, A., Marfisee, M., **Shoptaw, S.**, Greengold, B., de Castro, V., George, D., Leake, B. Correlates of alcohol use among methadone-maintained adults. *Drug & Alcohol Dependence*. 2009; Apr 1; 101(1-2):124-7. PMID: PMC2681228
  100. **Shoptaw, S.J.**, Kao, U., Heinzerling, K., Ling, W. Treatment for amphetamine withdrawal. *Cochrane Database System Rev*. 2009; Apr 15;(2):CD003021 PMID: PMC Not Applicable
  101. Hudson, A.L., Nyamathi, A., Bhattacharya, D., Marlow, E., **Shoptaw, S.** Marfisee, M., Leake, B. Impact of prison status on HIV-related risk behaviors. *AIDS Behavior*. 2009; May 20. PMID: PMC2945614
  102. Ober, A., **Shoptaw, S.**, Wang, J., Gorbach, P., Weiss, R.E. Factors associated with event-level stimulant use during sex in a sample of low-income men who have sex with men in Los Angeles. *Drug & Alcohol Dependence*. 2009; Jun 1; 102 (1-3):123-9. PMID: PMC2649661
  103. Ostrow, D., Plankey, M., Cox, C., Li, X., **Shoptaw, S.**, Jacobson, L., Stall, R., Specific sex drug combinations contributes to the majority of recent HIV seroconversions among MSM in the MACS. *Journal of Acquired Immune Deficiency Syndromes*. 2009; Jul; 51(3):349-355. PMID: PMC3074969
  104. Kahn, R., Biswas, K., Childress, A.R., **Shoptaw, S.**, Fudala, P.J., Gorgon, L., Montoya, I., Collins, J., McSherry, F., Li, S.H., Chiang, N., Alathari, H., Watson, D., Liberto, J., Beresford, T., Stock, C., Wallace, C., Gruber, V., Elkashef, A. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. *Drug & Alcohol Dependence*. 2009; Jul 1; 103(1-2):59-64. PMID: PMC2774896
  105. Newman, P.A., Lee, S.J., Duan, N., Rudy, E., Nakazono, T.K., Boscardin, J., Kakinami, L., **Shoptaw, S.**, Diamant, A., Cunningham, W.E. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). *Health Service Research*. 2009; Dec; 44(6):2167-79. PMID: PMC2796320
  106. Zorick, T., Sevak, R.J., Miotto, K., **Shoptaw, S.**, Swanson, A.N., Clement, C., De La Garza, R., Newton, T.F., London, E.D. Pilot safety evaluation of varenicline for the treatment of

- methamphetamine dependence. *Journal of Experimental Pharmacology*. 2009; Dec 1; (2):13-18. PMID: PMC2915574
107. Young, S.D., **Shoptaw, S.**, Weiss, R.E., Munjas, B., Gorbach, P.M. Predictors of unrecognized HIV infection among poor and ethnic men who have sex with men in Los Angeles. *AIDS Behavior*. 2009; Dec 31. PMID: PMC3029495
  108. Nyamathi, A, **Shoptaw, S.**, Cohen, A, Greengold, B, Nyamathi, K, Marfisee, M, de Castro, V, Khalilifard, F, George, D, Leake, B. Effect of motivational interviewing on reduction of alcohol use. *Drug & Alcohol Dependence*. 2010; Feb 1; 107(1):23-30. PMID: PMC3383096
  109. Costello, MR, Mandelkern, MA, **Shoptaw, S.**, Shulenberger, S, Baker, SK, Abrams, AL, Xia, C, London, ED, Brody, AL. Effects of treatment for tobacco dependence on resting cerebral glucose metabolism. *Neuropsychopharmacology*. 2010 Feb; 35(3):605-12. PMID: PMC2813904
  110. Lin, C, Wu, Z, Rou, K, Yin, W, Wang, C, **Shoptaw, S**, Detels, R. Structural-level factors affecting implementation of the methadone maintenance therapy program in China. *J Subst Abuse Treat*. 2010; Mar; 38(2):119-27. PMID: PMC2814942
  111. Das, M, Santos, D, Matheson, T, Santos, GM, Chu, P, Vittinghoff, E, **Shoptaw, S**, Colfax, GN. Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men. *AIDS*. 2010 Apr 24;24(7):991-1000. PMID: PMC3619723
  112. Reback, CJ, Ling, D, **Shoptaw, S**, Rohde, J. Developing a text messaging risk reduction intervention for methamphetamine-using MSM: Research note. *Open AIDS J*. 2010 May 14; 4:116-22. PMID: PMC2905770
  113. Lin, C, Wu, Z, Rou, K, Pang, L, Cao, X, **Shoptaw, S**, Detels, R. Challenges in providing service in methadone maintenance therapy clinics in China: service providers' perceptions. *Int J Drug Policy*. 2010 May; 21(3):173-8. PMID: PMC2847064
  114. Heinzerling, KG, Swanson, AN, Kim, S, Cederblom, L, Moe, A, Ling, W, **Shoptaw, S**. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. *Drug Alcohol Depend*. 2010 Jun 1;109 (1-3):20-9. PMID: PMC2875545
  115. Brody, AL, London, ED, Olmstead, RE, Allen-Martinez, Z, Shulenberger, S, Costello, MR, Abrams, AL, Scheibal, D, Farahi, J, **Shoptaw, S**, Mandelkern, MA. Smoking-induced change in intrasynaptic dopamine concentration: Effect of treatment for tobacco dependence. *Psychiatry Res*. 2010 Sep 30; 183 (3):218-24. PMID: PMC2947623
  116. Menza, TW, Jameson, DR, Hughes, JP, Colfax, GN, **Shoptaw, S**, Golden, MR. Contingency management to reduce methamphetamine use and sexual risk among men who have sex with men: a randomized controlled trial. *BMC Public Health*. 2010 Dec 20; 10 (1):774. PMID: PMC3016390
  117. Ober, AJ, Iguchi, MY, Weiss, RE, Gorbach, PM, Heimer, R, Ouellet, LJ, **Shoptaw, S**,

- Anglin, MD, Zule, WA. The relative role of perceived partner risks in promoting condom use in a three-city sample of high-risk, low-income women. *AIDS Behav.* 2011 Oct; 15(7):1347-58  
PMCID: PMC3180610
118. Xu, H., Shen, Q., Yang, Z., **Shoptaw, S.** A quasi F-test functional linear models with functional covariates and its application to longitudinal data. *Stat Med.* 2011 Oct 15; 30(23):2842-53. PMCID: PMC not applicable.
119. Hudson, AL, Nyamathi, A, Bhattacharya, D, Marlow, E, **Shoptaw, S**, Marfisee, M, Leake, B. Impact of prison status on HIV-related risk behaviors. *AIDS Behav.* 2011 February;15(2): 340–346. PMCID: PMC2945614
120. Tross, S, Campbell, AN, Calsyn, DA, Metsch, LR, Sorensen, JL, **Shoptaw, S**, Haynes, L, Woody, GE, Malow, RM, Brown, LS, Feaster, DJ, Booth, RE, Mandler, RN, Masson, C, Holmes, BW, Colfax, G, Brooks, AJ, Hien, DA, Schackman, BR, Korthuis, PT, Miele, GM. Clinical Trials Network HIV Special Interest Group. NIDA’s Clinical Trials Network: An opportunity for HIV research in community substance abuse treatment programs. *Am J Drug Alcohol Abuse.* 2011 Sep;37(5):283-93. PMCID: PMC3361073.
121. Zorick, T, Sugar, CA, Helleman, G, **Shoptaw, S**, London, ED. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. *Drug Alcohol Depend.* 2011 Nov 1; 118(2-3):500-3. PMCID: PMC3181284
122. Ling, W, **Shoptaw, S**, Hillhouse, M, Bholat, MA, Charuvastra, C, Heinzerling, K, Chim, D, Annon, J, Dowling, PT, Doraimani, G. Double-blind placebo-controlled evaluation of the PROMETA protocol for methamphetamine dependence. *Addiction.* 2012 Feb; 107(2):361-9. Epub 2011 Nov 15. PMCID: PMC4122522
123. Lim, S.H., Ostrow, D., Stall, R., Chmiel, J., Herrick, A., **Shoptaw, S.**, Kao, U., Carrico, A., Plankey, M. Changes in stimulant drug use over time in the MACS: Evidence for resilience against stimulant drug use among men who have sex with men. *AIDS Behav.* 2012 Jan; 16(1):151-8. PMCID: PMC3133874
124. Heinzerling, K, McCracken, JT, Swanson, AN, Ray, L, **Shoptaw, SJ.** COMT Val158Met, BDNF Val66Met, and OPRM1Asn40Asp and methamphetamine dependence treatment response: Preliminary investigation. *J Clin Psychopharmacol.* 2012 Feb;32(1):135-7. PMCID: PMC3597465
125. Murphy, R.D., Gorbach, P.M., Weiss, R.E., Hucks-Ortiz, C., **Shoptaw, S.** Seroadaptation in a Sample of Very Poor Los Angeles Area Men Who Have Sex with Men. *AIDS & Behavior.* 2012, May 27 PMCID: PMC3479326.
126. Reback, CJ, **Shoptaw, S**, Downing, MJ. Prevention case management improves socioeconomic standing and reduces symptoms of psychological and emotional distress among transgender women. *AIDS Care.* 2012;24(9):1136-44. Epub 2012 Jun 7. PMCID: PMC not applicable.
127. Brensilver, M, Heinzerling, KH, Swanson, AN, **Shoptaw, SJ.** A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: Suggested guidelines for

treatment discontinuation/augmentation. *Drug & Alcohol Depend.* 2012 Sep 1;125(1-2):169-72. Epub 2012 Apr 23. PMID: PMC3418457

128. Landovitz, RJ, Fletcher, JB, Inzhakova, G, Lake, JE, **Shoptaw, S**, Reback, CJ. A novel combination HIV prevention strategy: Post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men. *AIDS Patient Care STDs.* 2012 Jun; 26(6):320-8. PMID: PMC3366332
129. Reback, CJ, Grant, DL, Fletcher, JB, Branson, CM, **Shoptaw, S**, Bowers, JR, Charania, M, Mansergh, G. Text messaging reduces HIV risk behaviors among methamphetamine-using men who have sex with men. *AIDS Behav.* 2012 Oct; 16(7):1993-2002. PMID: PMC not applicable.
130. Penniman-Dyer, T, **Shoptaw, S**, Guadamuz, T, Plankey, M, Kao, U, Ostrow, D, Chmiel, J, Herrick, A, Stall, R. Application of Syndemic Theory to Black men who have sex with men in the Multicenter AIDS Cohort Study. *J Urban Health.* 2012 Aug; 89(4):697-708. PMID: PMC3535137.
131. Strathdee, SA, **Shoptaw, S**, Dyer, TP, Quan, VM, Aramrattana, A; Substance Use Scientific Committee of the HIV Prevention Trials Network. Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention. *Curr Opin HIV AIDS.* 2012 Jul; 7(4):320-5. PMID: PMC3646543.
132. Brensilver, M, Heinzerling, KG, Swanson, AN, Telesca, D, Furst, BA, **Shoptaw, SJ**. Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. *Drug Alcohol Rev.* 2013 Jan;32(1):96-9. Epub 2012 Mar 4. PMID: PMC3371287
133. Heinzerling, KG, **Shoptaw, S**. Gender, Brain-derived neurotrophic Factor Val66Met, and frequency of methamphetamine use. *Gen Med.* 2012 Apr; 9(2):112-20. Epub 2012 Mar 23. PMID: PMC3322259
134. Cranston, RD, Murphy, R, Weiss, RE, Da Costa, M, Palefsky, J, **Shoptaw, S**, Gorbach, PM. Anal human papillomavirus infection in a street-based sample of drug using HIV positive men. *Int J STD AIDS.* 2012 Mar; 23(3):195-200. PMID: PMC3899933.
135. **Shoptaw, S**, Plankey, MW, Bordon, J, Kao, U, Cox, C, Li, X, Ostrow, DG, Stall, RC. Cumulative exposure to stimulants and immune function outcomes among HIV-positive and HIV-negative men and the Multicenter AIDS Cohort Study. *Int J STD AIDS.* 2012 Aug;23(8):576-80. PMID: PMC3576843
136. Brensilver, M, Heinzerling, KG, Swanson, AN, **Shoptaw, SJ**. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence. *Exp Clin Psychopharmacol.* 2012 Oct;20(5):430-5. PMID: PMC4035480.
137. Nyamathi, A, Branson, C, Idemudia, F, Reback, C, **Shoptaw, S**, Marfisee, M, Keenan, C, Khalilifard, F, Liu, Y, Yadav, K. Correlates of depressed mood among young stimulant-using homeless gay and bisexual men. *Issues Ment Health Nurs.* 2012 Oct;33(10):641-9. PMID: PMC3624023.

138. Holloway, IW, Cederbaum, JA, Ajayi, A, **Shoptaw, S**. Where are the young men in HIV prevention efforts? Comments on HIV prevention programs and research from young men who have sex with men in Los Angeles County. *J Prim Prev*. 2012 Dec;33(5-6):271-8. PMID: PMC3513361.
139. Herrick, AL, Lim, SH, Plankey, MW, Chmiel, JS, Guadamuz, TT, Kao, U, **Shoptaw, S**, Ostrow, D, Stall, R. Adversity and syndemic production among men participating in the Multicenter AIDS Cohort Study: A life-course approach. *Am J Public Health*. 2013 Jan;103(1):79-85. Epub 2012 Nov 15. PMID: PMC3518355.
140. Heinzerling, KG, Gadzhyan J, van Oudheusden H, Rodriguez, F, McCracken, J, **Shoptaw, S**. Pilot randomized trial of Bupropion for adolescent methamphetamine abuse/dependence. *J Adolesc Health*. 2013 Apr;52(4):502-5. PMID: PMC3608805
141. Young, SD, **Shoptaw, S**. Stimulant use among African American and Latino MSM social networking users. *J Addict Dis*. 2013;32(1):39-45. PMID: PMC3825678.
142. Herrick AL, Stall R, Chmiel JS, Guadamuz TE, Penniman T, **Shoptaw S**, Ostrow, D, Plankey, MW. It gets better: Resolution of internalized homophobia over time and associations with positive health outcomes among MSM. *AIDS Behav*. 2013 May;17(4):1423-30. PMID: PMC3708613.
143. **Shoptaw, S**, Montgomery, B, Williams, CT, El-Bassel, N, Aramrattana, A, Metsch, L, Metzger, DS, Kuo, I, Bastos, FI, Strathdee, SA. Not just the needle: the state of HIV-prevention science among substance users and future directions. *J Acquir Immune Defic Syndr*. 2013 Jul;63 Supp 2: S174-S178. PMID: PMC3739052.
144. Koblin, B, Mayer K, Eshleman, S, Wang, L, Mannheimer, S, del Rio, C, **Shoptaw, S**, Magnus, M, Buchbinder, S, Wilton, L, Ting-Yuan, L, Cummings, V, Piwowar-Manning, E, Fields, S, Griffith, S, Elharrar, V, Wheeler, D, for the HPTN 061 Protocol Team. Correlates of HIV acquisition in a cohort of black men who have sex with men in the United States: HIV Prevention Trials Network (HPTN) 061. *PLoS One*. 2013 Jul 26;8(7): e70413. PMID: PMC3724810
145. Swanson, AN, **Shoptaw, S**, Heinzerling, KG, Wade, AC, Worley, M, McCracken, J, Wilson, SA, Asarnow, J, London, ED. Up in smoke? A preliminary open-label trial of nicotine replacement therapy and cognitive behavioral motivational enhancement for smoking cessation among youth in Los Angeles. *Subst Use Misuse*. 2013 Dec;48(14):1553-62. PMID: PMC not applicable.
146. Landovitz, R.J., Tseng, C.H., Weissman, M., Haymer, M., Mendenhall, B., Rogers, K., Veniegas, R., Gorbach, P.M., Reback, C.J., **Shoptaw, S**. Epidemiology, sexual risk behavior, and HIV prevention practices of men who have sex with men using GRINDR in Los Angeles, California. *J Urban Health*. 2013 Aug;90(4):729-39. PMID: PMC3732683
147. Reback, CJ, Fletcher, JB, **Shoptaw, S**, Grella, CE. Methamphetamine and other substance use trends among street-recruited men who have sex with men, from 2008 to 2011. *Drug Alcohol Depend*. 2013 Nov 1;133(1):262-5. PMID: PMC3888192.

148. Dyer, T.P., Regan, R., Wilton, L., Harawa, N.T., Ou, S.S., Wang, L., **Shoptaw, S.** Differences in substance use, psychosocial characteristics and HIV-related sexual risk behavior between black men who have sex with men only (BMSMO) and black men who have sex with men and women (BMSMW) in six US cities. *Journal of Urban Health*. 2013 Dec;90(6):1181-93. PMID: PMC3853182.
149. Ling Murtaugh K, Krishnamurti T, Davis AL, Reback CJ, **Shoptaw S.** Spend today, clean tomorrow: Predicting methamphetamine abstinence in a randomized controlled trial. *Health Psychol*. 2013 Sep;32(9):958-66. PMID: PMC3940415.
150. Brensilver, M., Heinzerling, K.G., **Shoptaw, S.** Pharmacotherapy of amphetamine-type stimulant dependence: An update. *Drug Alcohol Rev*. 2013 Sep; 32(5):449-60. PMID: PMC4251965.
151. **Shoptaw S.** HIV prevention for people who use substances: evidence-based strategies. *J Food Drug Anal*. 2013 Dec;21(4): S91-S94. PMID: PMC4158848
152. Hser YI, Chang L, Wang GJ, Li MD, Rawson R, **Shoptaw S**, Normand J, Tai B. Capacity building and collaborative research on cross-national studies in the Asian region. *J Food Drug Anal*. 2013 Dec 1;21(4): S117-S122. PMID: PMC3931525
153. Marzinke MA, Clarke W, Wang L, Cummings V, Liu TY, Piwowar-Manning E, Breaud A, Griffith S, Buchbinder S, **Shoptaw S**, Del Rio C, Magnus M, Mannheimer S, Fields SD, Mayer KH, Wheeler DP, Koblin BA, Eshleman SH, Fogel JM. Nondisclosure of HIV Status in a Clinical Trial Setting: Antiretroviral Drug Screening Can Help Distinguish Between Newly Diagnosed and Previously Diagnosed HIV Infection. *Clin Infect Dis*. 2014 Jan;58(1):117-20. Epub 2013 Oct 2. PMID: PMC3864502.
154. Harawa N, Wilton L, Wang L, Mao C, Kuo I, Penniman T, **Shoptaw S**, Griffith S, Williams JK, Cummings V, Mayer K, Koblin B; HPTN 061. Types of Female Partners Reported by Black Men Who Have Sex with Men and Women (MSMW) and Associations with Intercourse Frequency, Unprotected Sex and HIV and STI Prevalence. *AIDS Behav*. 2014 Feb 13 (Epub ahead of print). PMID: PMC4169287.
155. Nyamathi A, Reback CJ, Salem BE, Zhang S, **Shoptaw S**, Branson CM, Leake B. Correlates of Self-Reported Incarceration Among Homeless Gay and Bisexual Stimulant-Using Young Adults. *West J Nurs Res*. 2015 Jun;37(6):799-811. Epub 2014 Apr 14. PMID: PMC4197114.
156. Pines HA, Gorbach PM, Weiss RE, **Shoptaw S**, Landovitz RJ, Javanbakht M, Ostrow DG, Stall RD, Plankey M. Sexual Risk Trajectories Among MSM in the United States: Implications for Pre-exposure Prophylaxis Delivery. *J Acquir Immune Defic Syndr*. 2014 Apr 15;65(5):579-86. PMID: PMC4026016.
157. Asarnow JR, Zeledon LR, D'Amico E, LaBorde A, Anderson M, Avina C, Arslanian T, Do MC, Harwood J, **Shoptaw S.** Depression and Health Risk Behaviors: Towards Optimizing Primary Care Service Strategies for Addressing Risk. *Prim Health Care*. 2014 Mar 1;4(1):152. PMID: PMC4189940

158. Stahlman S, Javanbakht M, Cochran S, Hamilton AB, **Shoptaw S**, Gorbach PM. Self-Reported Sexually Transmitted Infections and Sexual Risk Behaviors in the US Military: How Sex Influences Risk. *Sex Transm Dis*. 2014 Jun;41(6):359-64. PMID: PMC4232818.
159. Friedman MR, Stall R, Silvestre AJ, Mustanski B, **Shoptaw S**, Surkan PJ, Rinaldo CR, Plankey MW. Stuck in the Middle: Longitudinal HIV-Related Health Disparities Among Men Who Have Sex with Men and Women. *J Acquir Immune Defic Syndr*. 2014 Jun 1;66(2):213-20. PMID: PMC4030741.
160. Reback, C.J., **Shoptaw, S**. Getting Off: Development of an evidence-based, gay-specific cognitive behavioral therapy intervention for methamphetamine-abusing gay and bisexual men. *Addictive Behaviors*. 2014 Aug;39(8):1286-91. Epub 2011 Nov 26. PMID: PMC3326187.
161. Heinzerling KG, Swanson AN, Hall TM, Ba YY, Wu Y, **Shoptaw SJ**. Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. *Addiction*. 2014 Nov;109(11):1878-86. PMID: PMC4192025.
162. Fletcher JB, **Shoptaw S**, Peck JA, Reback CJ. Contingency Management Reduces Symptoms of Psychological and Emotional Distress among Homeless, Substance-dependent Men Who Have Sex with Men. *Ment Health Subst Use*. 2014 Nov 1;7(4):420-430. PMID: PMC4214612.
163. Marrazzo JM, del Rio C, Holtgrave DR, Cohen MS, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, **Shoptaw S**, Walensky RP, Dabis F, Sugarman J, Benson CA; International Antiviral Society-USA Panel. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2014 Jul 23-30;312(4):390-409. PMID: in process.
164. Chen I, Cummings V, Fogel JM, Marzinke MA, Clarke W, Connor MB, Griffith S, Buchbinder S, **Shoptaw S**, Rio CD, Magnus M, Mannheimer S, Wheeler DP, Mayer KH, Koblin BA, Eshleman SH. Low-level Viremia Early in HIV Infection. *J Acquir Immune Defic Syndr*. 2014 Dec 1;67(4):405-8. PMID: PMC4213245
165. Abdul-Khabir W, Hall T, Swanson AN, **Shoptaw S**. Intimate partner violence and reproductive health among methamphetamine-using women in Los Angeles: a qualitative pilot study. *J Psychoactive Drugs*. 2014 Sep-Oct;46(4):310-6. PMID: PMC4188630
166. Hall TM, **Shoptaw S**, Reback CJ. Sometimes Poppers Are Not Poppers: Huffing as an Emergent Health Concern among MSM Substance Users. *J Gay Lesbian Ment Health*. 2014 Jan 23;19(1):118-121. PMID: PMC4399803
167. Fletcher JB, **Shoptaw S**, Peck JA, Reback CJ. Contingency Management Reduces Symptoms of Psychological and Emotional Distress among Homeless, Substance-dependent Men Who Have Sex with Men. *Ment Health Subst Use*. 2014 Nov 1;7(4):420-430. PMID: PMC4214612
168. Nyamathi AM, Reback CJ, **Shoptaw S**, Salem BE, Zhang S, Farabee D, Khalilifard F. Impact of Community-Based Programs on Incarceration Outcomes Among Gay and Bisexual Stimulant-Using Homeless Adults. *Community Ment Health J*. 2015 Jan 1. [Epub ahead of print]

PMCID: PMC4490143

169. Landovitz RJ, Fletcher JB, **Shoptaw S**, Reback CJ. Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. *Open Forum Infect Dis*. 2015 Jan 1;2(1): ofu114. eCollection 2015. PMCID: PMC4396429
170. Reback CJ, Fletcher JB, **Shoptaw S**, Mansergh G. Exposure to Theory-Driven Text Messages is Associated with HIV Risk Reduction Among Methamphetamine-Using Men Who have Sex with Men. *AIDS Behav*. 2015 Jun;19 Suppl 2:130-41. PMCID: PMC in process
171. Worley MJ, **Shoptaw SJ**, Bickel WK, Ling W. Using behavioral economics to predict opioid use during prescription opioid dependence treatment. *Drug Alcohol Depend*. 2015 March 1;148:62-8. pii: S0376-8716(14)01998-X. PMCID: PMC in process.
172. Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, Leventhal A, **Shoptaw S**, Heinzerling K, London ED, Miotto K. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: A Double-Blind, Placebo-Controlled Laboratory Study. *Neuropsychopharmacology*. 25 Sep;40(10):2347-2356. PMCID: PMC4538349
173. Stahlman S, Javanbakht M, Cochran S, **Shoptaw S**, Hamilton AB, Gorbach PM. A comparison of self-reported sexual risk behaviours between US civilian and active duty military women. *Sex Health*. 2015 Apr 7. doi: 10.1071/SH14211. [Epub ahead of print] PMCID: PMC in process.
174. Friedman MR, Stall R, Plankey M, Wei C, **Shoptaw S**, Herrick A, Surkan PJ, Teplin L, Silvestre AJ. Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study. *AIDS*. 2015 Jun 1;29(9):1087-1096. PMCID: PMC in process.
175. Stahlman S, Javanbakht M, Cochran S, Hamilton AB, **Shoptaw S**, Gorbach PM. Mental Health and Substance Use Factors Associated With Unwanted Sexual Contact Among US Active Duty Service Women. *J Trauma Stress*. 2015 Jun;28(3):167-73. PMCID:PMC4396429
176. Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, **Shoptaw S**. Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions. *J Acquir Immune Defic Syndr*. 2015 Jun 1;69 Suppl 1:S155-61.. PMCID: PMC4443704.
177. Akhtar-Khaleel WZ, Cook RL, **Shoptaw S**, Surkan P, Stall R, Beyth RJ, Teplin LA, Plankey M. Trends and Predictors of Cigarette Smoking Among HIV Seropositive and Seronegative Men: The Multicenter Aids Cohort Study. *AIDS Behav*. 2015 Jun 21. [Epub ahead of print] PMCID: PMC in process.
178. Worley MJ, Heinzerling KG, **Shoptaw S**, Ling W. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain. *Exp Clin Psychopharmacol*. 2015 Dec;23(6):428-35. Epub 2015 Aug 24. PMID: 26302337
179. Chen I, Connor MB, Clarke W, Marzinke MA, Cummings V, Breaud A, Fogel JM, Laeyendecker O, Fields SD, Donnell D, Griffith S, Scott HM, **Shoptaw S**, del Rio C, Magnus



- M, Mannheimer S, Wheeler DP, Mayer KH, Koblin BA and Eshleman SH. Antiretroviral drug use and HIV drug resistance among HIV-infected Black men who have sex with men: HIV Prevention Trials Network 061. 2015. *J Acquir Immune Defic Syndr*. PMID: PMC4482803.
180. Stemmler MS, Hall TM, Prokopik P, **Shoptaw SJ**. Time-site survey of substance use, sexual behaviours and HIV-testing practices among women attending social venues in Prague. *Central European Journal of Public Health*. PMID: PMC in process.
181. Gelberg L, Andersen RM, Afifi AA, Leake BD, Arangua L, Vahidi M, Singleton K, Yacenda-Murphy J, **Shoptaw S**, Fleming MF, Baumeister SE. Project QUIT (Quit Using Drugs Intervention Trial): a randomized controlled trial of a primary care-based multi-component brief intervention to reduce risky drug use. *Addiction*. 2015 Nov 1;110(11):1777-90. PMID: PMC4948983
182. Williams JK, Wilton L, Magnus M, Wang L, Wang J, Dyer TP, Koblin BA, Hucks-Ortiz C, Fields SD, **Shoptaw S**, Stephenson R, O'Cleirigh C, Cummings V; HIV Prevention Trials Network 061 Study Team. Relation of Childhood Sexual Abuse, Intimate Partner Violence, and Depression to Risk Factors for HIV Among Black Men Who Have Sex With Men in 6 US Cities. *Am J Public Health*. 2015 Oct 15:e1-e9. PMID: PMC in progress. [Epub ahead of print]
183. Heinzerling KG, Demirdjian L, Wu Y, **Shoptaw S**. Single nucleotide polymorphism near CREB1, rs7591784, is associated with pretreatment methamphetamine use frequency and outcome of outpatient treatment for methamphetamine use disorder. *J Psychiatr Res*. 2015 Dec 12;74:22-29. PMID: 26736037
184. Schaper E, Padwa H, Urada D, **Shoptaw S**. Substance use disorder patient privacy and comprehensive care in integrated health care settings. *Psychol Serv*. 2016 Feb;13(1):105-9 PMID: 26845493 [PubMed - in process].
185. Okafor CN, Cook RL, Chen X, Surkan PJ, Becker JT, **Shoptaw S**, Martin E, Plankey MW. Trajectories of Marijuana Use among HIV-seropositive and HIV-seronegative MSM in the Multicenter AIDS Cohort Study (MACS), 1984–2013. *AIDS and Behavior*. 2017 Apr 1;21(4):1091-104. PMID: PMC5136352.
186. Akhtar-Khaleel WZ, Cook RL, **Shoptaw S**, Surkan PJ, Teplin LA, Stall R, Beyth RJ, Manini TM, Plankey M. Long-term cigarette smoking trajectories among HIV-seropositive and seronegative MSM in the multicenter AIDS cohort study. *AIDS and Behavior*. 2016 Aug;20(8):1713-21. PMID: PMC4945456
187. DeYoung, D. Z., Heinzerling, K. G., Swanson, A. N., Tsuang, J., Furst, B. A., Yi, Y., ... & **Shoptaw, S. J.** (2016). Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment. *J Clin Psychopharmacol*. 2016 Aug;36(4):347-54. PMID: PMC4927401 [Available 08-01-2017]
188. Salem BE, Nyamathi Anp A, Reback C, **Shoptaw S**, Zhang S, Nudelman O. Unmet physical and mental healthcare needs among stimulant-using gay and bisexual homeless men. *Issues Ment Health Nurs*. 2015;36(9):685-92. PMID: 26440871

189. Worley MJ, Heinzerling KG, Roche DJ, **Shoptaw S**. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. *Drug Alcohol Depend.* 2016 May 1;162:245-50. PMID: 26993372
190. Di J, Li Y, Friedman MR, Reddy S, Surkan PJ, **Shoptaw S**, Plankey M. Determining Survey Satisficing of Online Longitudinal Survey Data in the Multicenter AIDS Cohort Study: A Group-Based Trajectory Analysis. *JMIR Public Health Surveill.* 2016 Aug 8;2(2):e150. PMID: 27503107.
191. Carrico AW, Jain J, Discepola MV, Olem D, Andrews R, Woods WJ, Neilands TB, **Shoptaw S**, Gómez W, Dilworth SE, Moskowitz JT. A community-engaged randomized controlled trial of an integrative intervention with HIV-positive, methamphetamine-using men who have sex with men. *BMC Public Health.* 2016 Jul 30;16:673. PMCID: PMC4967339
192. Chen I, Huang W, Connor MB, Frantzell A, Cummings V, Beauchamp GG, Griffith S, Fields SD, Scott HM, **Shoptaw S**, Del Rio C, Magnus M, Mannheimer S, Tieu HV, Wheeler DP, Mayer KH, Koblin BA, Eshleman SH. CXCR4-using HIV variants in a cohort of Black men who have sex with men: HIV Prevention Trials Network 061. *HIV Clin Trials.* 2016 Jul;17(4):158-64. PMCID: PMC5003405.
193. Friedman MR, Coulter RW, Silvestre AJ, Stall R, Teplin L, **Shoptaw S**, Surkan PJ, Plankey MW. Someone to count on: social support as an effect modifier of viral load suppression in a prospective cohort study. *AIDS Care.* 2016 Jul 25:1-12. PMCID: PMC5571899.
194. [Okafor CN, Cook RL, Chen X, Surkan PJ, Becker JT, **Shoptaw S**, Martin E, Plankey MW. Prevalence and correlates of marijuana use among HIV-seropositive and seronegative men in the Multicenter AIDS Cohort Study (MACS), 1984–2013. *The American journal of drug and alcohol abuse.* 2017 Sep 3;43(5):556-66. PMCID: PMC5415427.]
195. [Friedman MR, Stall R, Plankey M, **Shoptaw S**, Herrick AL, Surkan PJ, Teplin L, Silvestre AJ. Stability of Bisexual Behavior and Extent of Viral Bridging Behavior Among Men Who Have Sex with Men and Women. *Archives of Sexual Behavior.* 2017 May;46(4):903-912. PMCID: PMC5438760]
196. [Chen I, Chau G, Wang J, Clarke W, Marzinke MA, Cummings V, Breaud A, Laeyendecker O, Fields SD, Griffith S, Scott HM, **Shoptaw S**, Del Rio C, Magnus M, Mannheimer S, Tieu HV, Wheeler DP, Mayer KH, Koblin BA, Eshleman SH. Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061). *PLoS One.* 2016 Dec 9;11(12):e0167629. PMCID: PMC5147928.]
197. [Gelberg L, Andersen RM, Rico MW, Vahidi M, Rey GN, **Shoptaw S**, Leake BD, Serota M, Singleton K, Baumeister SE. A pilot replication of QUIT, a randomized controlled trial of a brief intervention for reducing risky drug use, among Latino primary care patients. *Drug & Alcohol Dependence.* 2017 Oct 1;179:433-40. PMCID: PMC5796764]
198. [Fulcher JA, **Shoptaw S**, Makgoeng SB, Elliott J, Ibarrrondo FJ, Ragsdale A, Brookmeyer R, Anton PA, Gorbach PM. Recent Methamphetamine Use is Associated with Increased Rectal

- Mucosal Inflammatory Cytokines Regardless of HIV-1 Serostatus. *Journal of acquired immune deficiency syndromes (1999)*. 2018 Feb. PMID: PMC5810127.]
199. [Aralis HJ, **Shoptaw S**, Brookmeyer R, Ragsdale A, Bolan R, Gorbach PM. Psychiatric Illness, Substance Use, and Viral Suppression Among HIV-Positive Men of Color Who Have Sex with Men in Los Angeles. *AIDS and Behavior*. 2018. PMID: PMC6497144.]
  200. [Birath JB, Briones M, Amaya S, **Shoptaw S**, Swanson AN, Tsuang J, Furst B, Heinzerling K, Obermeit L, Maes L, McKay C. Ibudilast may improve attention during early abstinence from methamphetamine. *Drug & Alcohol Dependence*. 2017 Sep 1;178:386-90. PMID: 28704767.]
  201. [Carrico AW, Cherenack EM, Roach ME, Riley ED, Oni O, Dilworth SE, **Shoptaw S**, Hunt P, Roy S, Pallikkuth S, Pahwa S. Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. *AIDS*. 2018 Mar 27;32(6):767-771. PMID: PMC5912167.]
  202. [**Shoptaw S**, Landovitz RJ, Reback CJ. Contingent vs. Non-Contingent Rewards: Time-based Intervention Response Patterns among Stimulant-using Men who have Sex with Men. *J Subst Abuse Treat*. 2017 Jan;72:19-24. . PMID: 27938777.]
  203. [Ray LA, Bujarski S, **Shoptaw S**, Roche DJ, Heinzerling K, Miotto K. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial. *Neuropsychopharmacology*. 2017;42(9):1776-88. PMID: PMC5520778.]
  204. [Worley MJ, Heinzerling KG, **Shoptaw S**, Ling W. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. *Addiction*. 2017;112(7):1202-9. PMID: PMC5461207.]
  205. [Cerrada CJ, Dzibur E, Blackman KC, Mays V, **Shoptaw S**, Huh J. Development of a Just-in-Time Adaptive Intervention for Smoking Cessation Among Korean American Emerging Adults. *Int J Behav Med*. 2017 Oct;24(5):665-672. PMID: PMC5519441.]
  206. [Akhtar-Khaleel WZ, Cook RL, **Shoptaw S**, Miller EN, Sacktor N, Surkan PJ, Becker J, Teplin LA, Beyth RJ, Price C, Plankey M. Association of midlife smoking status with change in processing speed and mental flexibility among HIV-seropositive and HIV-seronegative older men: the Multicenter AIDS Cohort Study. *J Neurovirol*. 2017 Apr;23(2):239-249. PMID: PMC5663220.]
  207. [Nyamathi A, Reback CJ, **Shoptaw S**, Salem BE, Zhang S, Yadav K. Impact of Tailored Interventions to Reduce Drug Use and Sexual Risk Behaviors Among Homeless Gay and Bisexual Men. *Am J Mens Health*. 2017 Mar;11(2):208-220. PMID: PMC5675281.]
  208. [Ober AJ, Dangerfield DT 2nd, **Shoptaw S**, Ryan G, Stucky B, Friedman SR. Using a “Positive Deviance” Framework to Discover Adaptive Risk Reduction Behaviors Among High-Risk HIV Negative Black Men Who Have Sex with Men. *AIDS Behav*. 2018 May;22(5):1699-1712. PMID: PMC6334847.]

209. [Dangerfield DT, Ober AJ, Smith LR, **Shoptaw S**, Bluthenthal RN. Exploring and Adapting a Conceptual Model of Sexual Positioning Practices and Sexual Risk Among HIV-Negative Black Men Who Have Sex With Men. *J Sex Res.* 2018 Oct;55(8):1022-1032. PMID: PMC6105556.]
210. [Zhang Y, Clarke W, Marzinke MA, Piwowar-Manning E, Beauchamp G, Breaud A, Hendrix CW, Cloherty GA, Emel L, Rose S, Hightow-Weidman L, Siegel M, **Shoptaw S**, Fields SD, Wheeler D, Eshleman SH.. Evaluation of a multi-drug assay for monitoring adherence to a regimen for HIV pre-exposure prophylaxis in a clinical study (HIV Prevention Trials Network 073). *Antimicrob Agents Chemother.* 2017 Jun 27;61(7). pii: e02743-16. PMID: PMC5487665.]
211. [Kelso-Chichetto NE, Plankey M, Sheps DS, Abraham AG, Chen X, **Shoptaw S**, Kaplan RC, Post WS, Cook RL. The impact of long-term moderate and heavy alcohol consumption on incident atherosclerosis among persons living with HIV. *Drug Alcohol Depend.* 2017 Dec 1;181:235-241. PMID: PMC5789452.]
212. [Ladapo JA, Richards AK, DeWitt CM, Harawa NT, **Shoptaw S**, Cunningham WE, Mafi JN. Disparities in the Quality of Cardiovascular Care Between HIV-Infected Versus HIV-Uninfected Adults in the United States: A Cross-Sectional Study. *J Am Heart Assoc.* 2017 Nov 14;6(11). pii: e007107. PMID: PMC5721786.]
213. [Chen I, Zhang Y, Cummings V, Cloherty GA, Connor M, Beauchamp G, Griffith S, Rose S, Gallant J, Scott HM, **Shoptaw S**, Del Rio C, Kuo I, Mannheimer S, Tieu HV, Hurt CB, Fields SD, Wheeler DP, Mayer KH, Koblin BA, Eshleman SH. Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States. *AIDS Res Hum Retroviruses.* 2017 Jul;33(7):745-748. PMID: PMC5512295.]
214. [Roche DJ, Worley MJ, Courtney KE, Bujarski S, London ED, **Shoptaw S**, Ray LA. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder. *Psychopharmacology (Berl).* 2017;234(13):1997-2007. PMID: PMC5480611.]
215. [Levy ME, Phillips G 2nd, Magnus M, Kuo I, Beauchamp G, Emel L, Hucks-Ortiz C, Hamilton EL, Wilton L, Chen I, Mannheimer S, Tieu HV, Scott H, Fields SD, Del Rio C, **Shoptaw S**, Mayer K. A Longitudinal Analysis of Treatment Optimism and HIV Acquisition and Transmission Risk Behaviors Among Black Men Who Have Sex with Men in HPTN 061. *AIDS Behav.* 2017 Oct;21(10):2958-2972. PMID: PMC5623129.]
216. [Cook R, Quinn B, Heinzerling K, **Shoptaw S**. Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence. *Addiction.* 2017 Jun;112(6):1077-1085. PMID: PMC5984202.]
217. [Okafor CN, Gorbach PM, Ragsdale A, Quinn B, **Shoptaw S**. Correlates of Preexposure Prophylaxis (PrEP) Use among Men Who Have Sex with Men (MSM) in Los Angeles, California. *J Urban Health.* 2017 Oct;94(5):710-715. PMID: PMC5610125.]
218. [Brooks SJ, Lochner C, **Shoptaw S**, Stein DJ (2017). Using the research domain criteria (RDoC) to conceptualize impulsivity and compulsivity in relation to addiction. *Prog Brain Res.*

2017;235:177-218. PMID: 29054288.]

219. [Hermanstyne, KA, **Shoptaw, S**, & Cunningham, W. (2018). Associations of types of substances with condomless sex in vulnerable people living with HIV/AIDS. *J HIV AIDS Soc Serv*, 2018 Apr 3;17(2):118-26. PMID: Not Applicable.]
220. [Zhang SX, **Shoptaw S**, Reback CJ, Yadav K, Nyamathi AM. Cost-effective way to reduce stimulant-abuse among gay/bisexual men and transgender women: a randomized clinical trial with a cost comparison. *Public Health*. 2018 Jan;154:151-160. PMID: PMC5745270.]
221. [Bai S, Zeledon LR, D'Amico EJ, **Shoptaw S**, Avina C, LaBorde AP, Anderson M, Fitzpatrick OM, Asarnow JR. (2018). Reducing Health Risk Behaviors and Improving Depression in Adolescents: A Randomized Controlled Trial in Primary Care Clinics. *J Pediatr Psychol*. 2018 Oct 1;43(9):1004-1016.. PMID: PMC6147756.]
222. [Hermanstyne KA, Green Jr HD, Cook R, Tieu HV, Dyer TV, Hucks-Ortiz C, Wilton L, Latkin C, **Shoptaw S**. Social Network Support and Decreased Risk of Seroconversion in Black MSM: Results of the BROTHERS (HPTN 061) Study. *J Acquir Immune Defic Syndr*. 2018 Jun 1;78(2):163-168. PMID: PMC5953785.]
223. [Briones M, **Shoptaw S**, Cook R, Worley M, Swanson AN, Moody DE, Fang WB, Tsuang J, Furst B, Heinzerling K. Varenicline treatment for methamphetamine dependence: A randomized, double-blind Phase II clinical trial. *Drug Alcohol Depend*. 2018 Aug 1;189:30-36.. PMID: PMC6391991.]
224. [Davey DJ, Farley E, Towriss C, Gomba Y, Bekker LG, Gorbach P, **Shoptaw S**, Coates T, Myer L. Risk perception and sex behaviour in pregnancy and breastfeeding in high HIV prevalence settings: Programmatic implications for PrEP delivery. *PloS One*. 2018 May 14;13(5):e0197143. PMID: PMC5951545.]
225. [Shover CL, Javanbakht M1, **Shoptaw S**, Bolan RK, Lee SJ, Parsons JT, Rendina J, Gorbach PM. HIV Preexposure Prophylaxis Initiation at a Large Community Clinic: Differences Between Eligibility, Awareness, and Uptake. *American Journal of Public Health*. 2018 Aug 23:e1-e10. PMID: PMC6137770.]
226. [Javanbakht M, Ragsdale A, **Shoptaw S**, Gorbach PM. Transactional Sex among Men Who Have Sex with Men: Differences by Substance Use and HIV Status. *J Urban Health*. 2019 Jun;96(3):429-441. PMID: PMC6565772.]
227. [Aralis HJ, **Shoptaw S**, Brookmeyer R, Ragsdale A, Bolan R, Gorbach PM. Psychiatric Illness, Substance Use, and Viral Suppression Among HIV-Positive Men of Color Who Have Sex with Men in Los Angeles. *AIDS Behav*. 2018 Oct;22(10):3117-3129. PMID: PMC6497144.]
228. [Wheeler, D. P., Lucas, J., Wilton, L., Nelson, L. E., Hucks-Ortiz, C., Watson, C. C., Hutchinson, C., Mayer, K. H., Kuo, I., Magnus, M., Beauchamp, G., **Shoptaw, S.**, Emel, L. M., Chen, Y. Q., Hightow-Weidman, L., Fields, S. D. Building effective multilevel HIV prevention partnerships with Black men who have sex with men: experience from HPTN 073, a pre-exposure prophylaxis study in three US cities. *J Int AIDS Soc*. 2018 Oct;21 Suppl 7:e25180.

PMCID: PMC6193312.]

229. [Dudovitz RN, Chung PJ, Reber S, Kennedy D, Tucker JS, **Shoptaw S**, Dosanjh KK, Wong MD. Assessment of exposure to high-performing schools and risk of adolescent substance use: a natural experiment. *JAMA Pediatr.* 2018 Dec 1;172(12):1135-1144. PMCID: PMC6350909.]
230. [Ray LA, Lim AC, **Shoptaw S**. What defines a clinically meaningful outcome in the treatment of substance use disorders: 'Getting your life back'. *Addiction.* 2019 Jan;114(1):18-20. PMID: 30426617.]
231. [Goodman-Meza D, Medina-Mora ME, Magis-Rodríguez C, Landovitz RJ, **Shoptaw S**, Werb D. Where Is the Opioid Use Epidemic in Mexico? A Cautionary Tale for Policymakers South of the US–Mexico Border. *Am J Public Health.* 2018 Nov 29:e1-e10. PMCID: PMC6301408.]
232. [Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, Rosenthal RN, Dunn KE, Strain EC, Ray L, **Shoptaw S**, Ait-Daoud Tiouririne N, Gunderson EW, Ransom J, Scott C, Leggio L, Caras S, Mason BJ, Litten RZ; National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial assessing Efficacy and Safety. *Alcohol Clin Exp Res.* 2019 Jan;43(1):158-169. PMCID: PMC6317996.]
233. [Li MJ, Okafor CN, Gorbach PM, **Shoptaw S**. Intersecting burdens: Homophobic victimization, unstable housing, and methamphetamine use in a cohort of men of color who have sex with men. *Drug Alcohol Depend.* 2018 Nov 1;192:179-185. PMCID: PMC6200602.]
234. [Carrico AW, Gómez W, Jain J, **Shoptaw S**, Discepola MV, Olem D, Lagana-Jackson J, Andrews R, Neilands TB, Dilworth SE, Evans JL. Randomized controlled trial of a positive affect intervention for methamphetamine users. *Drug Alcohol Depend.* 2018 Nov 1;192:8-15. PMCID: PMC6200638.]
235. [Hermanstynne KA, Green HD, Tieu HV, Hucks-Ortiz C, Wilton L, **Shoptaw S**. The Association Between Condomless Anal Sex and Social Support Among Black Men Who Have Sex With Men (MSM) in Six US Cities: A Study Using Data from the HIV Prevention Trials Network BROTHERS Study (HPTN 061). *AIDS Behav.* 2019 Jun;23(6):1387-1395. PMCID: PMC6754862.]
236. [Fulcher JA, Hussain SK, Cook R, Li F, Tobin NH, Ragsdale A, **Shoptaw S**, Gorbach PM, Aldrovandi GM. Effects of Substance Use and Sex Practices on the Intestinal Microbiome During HIV-1 Infection. *J Infect Dis.* 2018 Oct 5;218(10):1560-1570. PMCID: PMC6692862.]
237. [Gorbach PM, Javanbakht M, Shover CL, Bolan RK, Ragsdale A, **Shoptaw S**. Associations Between Cannabis Use, Sexual Behavior, and STIs/HIV in a Cohort of Young Men Who Have Sex with Men. *Sex Transm Dis.* 2019 Feb;46(2):105-111. PMCID: PMC6342487.]
238. [Panagiotoglou D, Olding M, Enns B, Feaster DJ, Del Rio C, Metsch LR, Granich RM, Strathdee SA, Marshall BD, Golden MR, **Shoptaw S**. Building the Case for Localized

Approaches to HIV: Structural Conditions and Health System Capacity to Address the HIV/AIDS Epidemic in Six US Cities. *AIDS Behav.* 2018 Sep;22(9):3071-3082. PMID: PMC6076864.]

239. [Okafor CN, Barnett W, Zar HJ, Nhapi R, Koen N, **Shoptaw S**, Stein DJ. Associations of emotional, physical, or sexual intimate partner violence and depression symptoms among South African women in a prospective cohort study. *J Interpers Violence.* 2018 Aug 30:886260518796522. PMID: PMC6486451.]
240. [Passaro RC, Ramsey K, Segura ER, Lake JE, Reback CJ, Clark JL, **Shoptaw S**. Speed kills: Associations between methamphetamine use, HIV infection, tobacco use, and accelerated mortality among gay and bisexual men in Los Angeles, CA 20 years after methamphetamine dependence treatment. *Drug Alcohol Depend.* 2019 Feb 1;195:164-169.. PMID: PMC6512788.]
241. [Dyer TV, Khan MR, Regan R, Harawa NT, Nelson LE, Wilton L, Wang L, Peng L, San Ou S, **Shoptaw S**. Differential Patterns of Risk and Vulnerability Suggest the Need for Novel Prevention Strategies for Black Bisexual Men in the HPTN 061 Study. *J Acquir Immune Defic Syndr.* 2018 Aug 15;78(5):491-498.. PMID: PMC6336193.]
242. [Okafor CN, Christodoulou J, Bantjes J, Qondela T, Stewart J, **Shoptaw S**, Tomlinson M, Rotherman-Borus MJ. Understanding HIV Risk Behaviors Among Young Men in South Africa: A Syndemic Approach. *AIDS Behav.* 2018 Dec;22(12):3962-3970. PMID: PMC6330132.]
243. [Carrico AW, Flentje A, Kober K, Lee S, Hunt P, Riley ED, **Shoptaw S**, Flowers E, Dilworth SE, Pahwa S, Aouizerat BE. Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection. *Brain Behav Immun.* 2018 Jul;71:108-115. PMID: PMC6003871.]
244. [Cunningham WE, Weiss RE, Nakazono T, Malek MA, **Shoptaw SJ**, Ettner SL, Harawa NT. Effectiveness of a peer navigation intervention to sustain viral suppression among HIV-positive men and transgender women released from jail: the LINK LA randomized clinical trial. *JAMA Intern Med.* 2018 Apr 1;178(4):542-553. PMID: PMC5885257.]
245. [Scott H, Vittinghoff E, Irvin R, Liu A, Nelson L, Del Rio C, Magnus M, Mannheimer S, Fields S, Van Tieu H, Kuo I, **Shoptaw S**, Grinsztejn B, Sanchez J, Wakefield S, Fuchs JD, Wheeler D, Mayer KH, Koblin BA, Buchbinder S. Development and Validation of the Personalized Sexual Health Promotion (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States. *AIDS Behav.* 2019 Jul 27. [Epub ahead of print]. PMID: 31352633.]
246. [Shover CL, **Shoptaw S**, Javanbakht M, Lee SJ, Bolan RK, Cunningham NJ, Beymer MR, DeVost MA, Gorbach PM. Mind the gaps: prescription coverage and HIV incidence among patients receiving pre-exposure prophylaxis from a large federally qualified health center in Los Angeles, California. *AIDS Behav.* 2019 Oct;23(10):2730-2740. PMID: PMC6863609.]
247. [Meanley SP, Stall RD, Hawk ME, Surkan PJ, **Shoptaw SJ**, Matthews DD, Teplin LA, Egan JE, Plankey MW. Multifactorial discrimination, discrimination salience, and prevalent experiences of internalized homophobia in middle-aged and older MSM. *Aging Ment Health.*

2019 Apr 2:1-8. PMID: 30938175.]

248. [Tsuyuki K, **Shoptaw SJ**, Ransome Y, Chau G, Rodriguez-Diaz CE, Friedman RK, Srithanaviboonchai K, Li S, Mimiaga MJ, Mayer KH, Safren SA. The Longitudinal Effects of Non-injection Substance Use on Sustained HIV Viral Load Undetectability Among MSM and Heterosexual Men in Brazil and Thailand: The Role of ART Adherence and Depressive Symptoms (HPTN 063). *AIDS Behav.* 2019 Mar;23(3):649-660. PMID: PMC6414080.]
249. [Takada S, Ettner SL, Harawa NT, Garland WH, **Shoptaw SJ**, Cunningham WE. Life Chaos is Associated with Reduced HIV Testing, Engagement in Care, and ART Adherence Among Cisgender Men and Transgender Women upon Entry into Jail. *AIDS Behav.* 2019 Aug 8. PMID: 31396766.]
250. [Goodman-Meza D, **Shoptaw S**, Weiss RE, Nakazono T, Harawa NT, Takada S, Garland WH, Cunningham WE. Methamphetamine use drives decreases in viral suppression for people living with HIV released from a large municipal jail: Results of the LINK LA clinical trial. *Drug Alcohol Depend.* 2019 Sep 1;202:178-84. PMID: PMC6686887.]
251. [Chichetto NE, Plankey MW, Abraham AG, Sheps DS, Ennis N, Chen X, Weber KM, **Shoptaw S**, Kaplan RC, Post WS, Cook RL. The Impact of Past and Current Alcohol Consumption Patterns on Progression of Carotid Intima-Media Thickness Among Women and Men Living with HIV Infection. *Alcohol Clin Exp Res.* 2019 Apr;43(4):695-703. PMID: PMC6443465.]
252. [Okafor CN, Plankey MW, Li M, Chen X, Surkan PJ, **Shoptaw S**, Martin E, Cohen R, Sacktor N, Cook RL. Association of marijuana use with changes in cognitive processing speed and flexibility for 17 Years in HIV-seropositive and HIV-seronegative men. *Subst Use Misuse.* 2019 Mar 21;54(4):525-37. PMID: PMC6443451.]
253. [Cook RR, Fulcher JA, Tobin NH, Li F, Lee D, Javanbakht M, Brookmeyer R, **Shoptaw S**, Bolan R, Aldrovandi GM, Gorbach PM. Effects of HIV viremia on the gastrointestinal microbiome of young MSM. *AIDS.* 2019 Apr 1;33(5):793-804. PMID: PMC6422698.]
254. [Shoptaw S, Nguyen DB, Giang LM. Prescribing in primary care: art versus algorithm. *Lancet Psychiatry.* 2019 Nov;6(11):882-884. PMID: 31588044.]
255. [Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, Ali R, Tran LT, Rehm J, Torrens M, **Shoptaw S**. Responding to global stimulant use: challenges and opportunities. *Lancet.* 2019 Nov 2;394(10209):1652-1667. PMID: PMC6924572.]
256. [Yamamoto A, Needleman J, Gelberg L, Kominski G, **Shoptaw S**, Tsugawa Y. Association between homelessness and opioid overdose and opioid-related hospital admissions/emergency department visits. *Soc Sci Med.* 2019 Dec;242:112585. PMID: 31634808.]
257. [Passaro RC, Segura ER, Lama JR, Sanchez J, Lake JE, **Shoptaw S**, Clark JL. High-Risk, but Hidden: Binge Drinking among Men Who Have Sex with Men and Transgender Women in Lima, Peru, 2012-2014. *Subst Use Misuse.* 2019 Nov 4:1-6.[Epub ahead of print]. PMID: 31682179.]



258. [Fulcher JA, Li F, Cook RR, Zabih S, Louie A, Okochi H, Tobin NH, Gandhi M, **Shoptaw S**, Gorbach PM, Aldrovandi GM. Rectal microbiome alterations associated with oral hiv pre-exposure prophylaxis. *Open Forum Infect Dis*. 2019 Oct 29;6(11):ofz463.]
259. [Cook RR, Fulcher JA, Tobin NH, Li F, Lee DJ, Woodward C, Javanbakht M, Brookmeyer R, **Shoptaw S**, Bolan R, Aldrovandi GM. Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men. *Sci Rep*. 2019 Oct 16;9(1):14840. PMID: PMC6795845.]
260. [Nosyk B, Zang X, Krebs E, Min JE, Behrends CN, Del Rio C, Dombrowski J, Feaster DJ, Golden M, Marshall BD, Mehta SH, Metsch L, Schackman BR, **Shoptaw S**, Strathdee S. Ending the Epidemic in America Will Not Happen if the Status Quo Continues: Modeled Projections for Human Immunodeficiency Virus Incidence in 6 US Cities. *Clin Infect Dis*. 2019 Nov 27;69(12):2195-2198. PMID: 31609446.]
261. [Li MJ, Takada S, Okafor CN, Gorbach PM, **Shoptaw SJ**, Cole SW. Experienced homophobia and gene expression alterations in Black and Latino men who have sex with men in Los Angeles County. *Brain Behav Immun*. 2020 Jan;83:120-125. PMID: PMC6906252.]
262. [Li MJ, Briones MS, Heinzerling KG, Kalmin M, **Shoptaw SJ**. Ibudilast attenuates peripheral inflammatory effects of methamphetamine in patients with methamphetamine use disorder. *Drug Alcohol Depend*. 2019 Nov 26;206:107776. PMID: 31812878.]
263. [Javanbakht M, **Shoptaw S**, Ragsdale A, Brookmeyer R, Bolan R, Gorbach PM. Depressive Symptoms and Substance Use: Changes Overtime among a Cohort of HIV-positive and HIV-negative MSM. *Drug Alcohol Depend*. 2019 Nov 27;207:107770. PMID: 31841750.]
264. [Krebs E, Zang X, Enns B, Min JE, Behrends C, Del Rio C, Dombrowski J, Feaster D, Gebo KA, Golden M, Marshall BM, Metsch LR, Schackman B, **Shoptaw S**, Strathdee SA, Nosyk B, on behalf of the localized HIV modeling study group. The impact of localized implementation: determining the cost-effectiveness of HIV prevention and care interventions across six U.S. cities. *AIDS*. 2019 Dec 2. [Epub ahead of print]. PMID: 31794521.]
265. [Ling W, **Shoptaw S**, Goodman-Meza D. Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation. *Subst Abuse Rehabil*. 2019 Nov 29;10:69-78. PMID: PMC6889966.]
266. [Heinzerling KG, Briones M, Thames AD, Hinkin CH, Zhu T, Wu YN, **Shoptaw SJ**. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder. *J Neuroimmune Pharmacol*. 2019 Dec 9. [Epub ahead of print]. PMID: 31820289.]
267. [Okafor CN, Stein DJ, Dannatt L, Ipsier J, van Nunen LJ, Lake MT, Krishnamurti T, London ED, **Shoptaw S**. Contingency management treatment for methamphetamine use disorder in South Africa. *Drug and Alcohol Review*. 2019 Dec 21. [Epub ahead of print]. PMID: 31863530.]
268. [Carrico AW, Neilands TB, Dilworth SE, Evans JL, Gómez W, Jain J, Gandhi M, **Shoptaw S**, Horvath KJ, Coffin L, Discepola MV, Andrews R, Woods WJ, Feaster DJ, Moskowitz JT..

Randomized controlled trial of a positive affect intervention to reduce HIV viral load among sexual minority men who use methamphetamine. *J Int AIDS Soc.* 2019 Dec;22(12):e25436. PMID: PMC6924317.]

269. [Joseph Davey DL, Pintye J, Baeten JM, Aldrovandi G, Baggaley R, Bekker LG, Celum C, Chi BH, Coates TJ, Haberer JE, Heffron R, Kinuthia J, Matthews LT, McIntyre J, Moodley D, Mofenson LM, Mugo N, Myer L, Mujugira A, **Shoptaw S**, Stranix-Chibanda L, John-Stewart G, PrEP in Pregnancy Working Group. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. *Journal of the International AIDS Society.* 2020 Jan;23(1):e25426. PMID: PMC6948023.]
270. [Okafor CN, Li MJ, Hucks-Ortiz C, Mayer KH, **Shoptaw S**. Disclosure of HIV Status and HIV Sexual Transmission Behaviors among HIV-Positive Black Men Who Have Sex with Men in the BROTHERS (HPTN 061) Study. *Journal of Urban Health.*:(13)1-12.]
271. [Quinn B, Gorbach PM, Okafor CN, Heinzerling KG, **Shoptaw S**. Investigating possible syndemic relationships between structural and drug use factors, sexual HIV transmission and viral load among men of colour who have sex with men in Los Angeles County. *Drug and alcohol review.* 2020 Feb;39(2):116.]
272. [Okafor CN, Plankey MW, Goodman-Meza D, Li M, Bautista KJ, Bolivar H, Phyllis TC, Brown TT, **Shoptaw SJ**. Association between self-reported marijuana use and incident diabetes in women and men with and at risk for HIV. *Drug and Alcohol Dependence.* 2020 Feb 20:107935.]
273. [Passaro RC, Segura ER, Gonzales-Saavedra W, Lake JE, Perez-Brumer A, Shoptaw S, Dille J, Cabello R, Clark JL. Sexual Partnership-Level Correlates of Intimate Partner Violence Among Men Who Have Sex with Men and Transgender Women in Lima, Peru. *Archives of Sexual Behavior.* 2020 Apr 8.]
274. [Nosyk B, Zang X, Krebs E, Enns B, Min JE, Behrends CN, del Rio C, Dombrowski JC, Feaster DJ, Golden M, Marshall BD, Mehta SH, Metsch LR, Pandya A, Schackman BR, **Shoptaw S**, Strathdee SA. Ending the HIV epidemic in the USA: an economic modelling study in six cities. *The Lancet HIV.* 2020 Jul;7(7):e491-e503.]
275. [Li MJ, Su E, Garland WH, Oksuzyan S, Lee SJ, Kao UH, Weiss RE, **Shoptaw SJ**. Trajectories of viral suppression in people living with HIV receiving coordinated care: Differences by comorbidities. *JAIDS Journal of Acquired Immune Deficiency Syndromes.* 2020 Aug 1;84(4):387-395..]
276. [Shoptaw S, Goodman-Meza D, Landovitz RJ. Collective call to action for HIV/AIDS community-based collaborative science in the era of COVID-19. *AIDS and Behavior.* 2020 Apr 16:1.]
277. [Nosyk B, Krebs E, Zang X, Piske M, Enns B, Min JE, Behrends CN, Del Rio C, Feaster DJ, Golden M, Marshall BD, Mehta SH, Meisel ZF, Metsch LR, Pandya A, Schackman BR, **Shoptaw S**, Strathdee SA on behalf of the Localized HIV Modeling Study Group. ‘Ending the Epidemic’ will not happen without addressing racial/ethnic disparities in the US HIV epidemic.

*Clinical Infectious Diseases*. 2020 May 19.]

278. [Schalet BD, Janulis P, Kipke MD, Mustanski B, Shoptaw S, Moore R, Baum M, Kim S, Siminski S, Ragsdale A, Gorbach PM. Psychometric Data Linking Across HIV and Substance Use Cohorts. *AIDS and Behavior*. 26 May 2020]
279. [Okafor CN, Hucks-Ortiz C, Hightow-Weidman LB, Magnus M, Emel L, Beauchamp G, Kuo I, Hendrix C, Mayer KH, **Shoptaw S**. Associations between Self-Reported Substance Use Behaviors and PrEP Acceptance and Adherence among Black MSM in the HPTN 073 Study. *Journal of Acquired Immune Deficiency Syndromes (1999)*. 2020 Sep 1;85(1):23-9..]
280. [Cook RR, Fulcher JA, Tobin NH, Li F, Lee D, Woodward C, Javanbakht M, Brookmeyer R, Shoptaw S, Bolan R, Aldrovandi GM. Combined effects of HIV and obesity on the gastrointestinal microbiome of young men who have sex with men. *HIV medicine*. 2020 Jul;21(6):365-77.]
281. [Pintye J, Davey DL, Wagner AD, John-Stewart G, Baggaley R, Bekker LG, Celum C, Chi BH, Coates TJ, Groves AK, Haberer JE, Heffron R, Kinuthia J, Matthews LT, McIntyre JA, Moodley D, Mofenson LM, Mugo N, Mujugira A, Myer L, **Shoptaw S**, Stranix-Chibanda L, Baeten JM, PrEP in Pregnancy Working Group. Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. *The Lancet HIV*. 2020 Aug 1;7(8):e582-92.]
282. [Blair CS, Javanbakht M, Comulada WS, Richter EI, Bolan R, **Shoptaw S**, Gorbach PM. Lubricants and rectal douching: associations with rectal gonorrhea, chlamydia, and/or syphilis infection among men who have sex with men. *International Journal of STD & AIDS*. 2020 Aug 4:0956462420938485.]
283. [Gorbach PM, Javanbakht M, Ragsdale A, Bolan RB, Flynn R, Mandler R, **Shoptaw S**. Methamphetamine Injection Among Young Men Who Have Sex With Men: Risk for Human Immunodeficiency Virus Transmission in a Los Angeles Cohort. *The Journal of Infectious Diseases*. 2020 Oct 1;222(Supplement\_5):S471-6.]
284. [Cassels S, Meltzer D, Loustalot C, Ragsdale A, **Shoptaw S**, Gorbach PM. Geographic Mobility, Place Attachment, and the Changing Geography of Sex among African American and Latinx MSM Who Use Substances in Los Angeles. *Journal of Urban Health*. 2020 Sep 29:1-4.]
285. [Krebs E, Zang X, Enns B, Min JE, Behrends CN, Del Rio C, Dombrowski JC, Feaster DJ, Gebo KA, Marshall BD, Mehta SH. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities. *The Journal of infectious diseases*. 2020 Oct 1;222(Supplement\_5):S301-11.]
286. [Mastro TD, Akolo C, **Shoptaw S**. Managing amphetamine use is critical to achieving HIV control – Editorial Comment. *AIDS*. 2020 Nov 1;34:1971-73.]
287. [Takada S, Gorbach P, Brookmeyer R, **Shoptaw S**. Associations of social capital resources and experiences of homophobia with HIV transmission risk behavior and HIV care continuum among men who have sex with men in Los Angeles. *AIDS Care*. 2020 Oct 13:1-2.]

288. [Pintye J, Davey DLJ, Wagner AD, John-Stewart G, Baggaley R, Bekker LG, Celum C, Chi BH, Coates TJ, Groves AK, Haberer JE, Heffron R, Kinuthia J, Matthews LT, McIntyre JA, Moodley D, Mofenson LM, Mugo N, Mujugira A, Myer L, **Shoptaw S**, Stranix-Chibanda L, Baeten JM; PrEP in Pregnancy Working Group. Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. *Lancet HIV*. 2020 Aug;7(8):e582-e592. PMID: PMC7587402.]
289. [**Shoptaw S**, Trivedi M, Potter JS. If there were an effective pharmacotherapy for cocaine use disorder, what would it do? *Addiction*. 2020 Dec 2.]
290. [Blair CS, Lake JE, Passaro RC, Chavez-Gomez S, Segura ER, Elliott J, Fulcher JA, **Shoptaw S**, Cabello R, Clark JL. HIV-1 Seroconversion is Not Associated with Prolonged Rectal Mucosal Inflammation. *Journal of Acquired Immune Deficiency Syndromes* (1999). 2020 Dec 17. PMID: 33351532.]
291. [Servis M, Fishman SM, Wallace MS, Henry SG, Ziedonis D, Ciccarone D, Knight KR, **Shoptaw S**, Dowling P, Suchard JR, Shah S. Responding to the Opioid Epidemic: Educational Competencies for Pain and Substance Use Disorder from the Medical Schools of the University of California. *Pain Medicine*. 2020 Dec 14. PMID: 33316051.]
292. [Strathdee SA, Bristow CC, Gaines T, **Shoptaw S**. Collateral Damage: A Narrative Review on Epidemics of Substance Use Disorders and their Relationships to Sexually Transmitted Infections in the United States. *Sexually Transmitted Diseases*. 2020 Dec 10. PMID: 33315749.]
293. [M.H. Trivedi, R. Walker, W. Ling, A. dela Cruz, G. Sharma, T. Carmody, U.E. Ghitza, A. Wahle, M. Kim, K. Shores-Wilson, S. Sparenborg, P. Coffin, J. Schmitz, K. Wiest, G. Bart, S.C. Sonne, S. Wakhlu, A.J. Rush, E.V. Nunes, and **S. Shoptaw**. Bupropion and Naltrexone in Methamphetamine Use Disorder. *New England Journal of Medicine*. 2021 Jan 14; 384(2):140-53.]

## **B. Research Papers- Peer Reviewed (In Press)**

1. .

## **C. Research Papers- Peer Reviewed (Submitted)**

### RESEARCH PAPERS (NON-PEER REVIEWED)

## **D. Research Papers- Non-Peer Reviewed**

1. Bholat, M.A., Ray, L., Brensilver, M., Ling, K., **Shoptaw, S**. Integration of behavioral medicine in primary care. *Primary Care*. 2012 Dec; 39(4):605-14. PMID not applicable.
2. Brensilver, M., Tariq, S., **Shoptaw, S**. Optimizing pain management through collaborations with behavioral and addiction medicine in primary care. *Primary Care*. 2012 Dec; 39(4):661-9. PMID not applicable.

**E. Research Papers- Non-Peer Reviewed (In Press)**

None

**F. Research Papers- Non-Peer Reviewed (Submitted)**

None

**CHAPTERS**

1. **Shoptaw, S.**, Rawson, R.A., Blum, M., Obert, J.L. (1994). Outpatient drug treatment manual for substance abusers with HIV. *Matrix Institute on addictions*. Beverly Hills, CA.
2. Ling, W., **Shoptaw, S.**, Wesson, D., Rawson, R.A., Compton, M., Klett, C.J. (1997). Treatment effectiveness score as an outcome measure in clinical trials. *NIDA research monograph 175: Medication Development for the Treatment of Cocaine Dependence: Issues in Clinical Efficacy Trials*, 208-220.
3. Nahom, D., **Shoptaw, S.**, Portnoff, M., Rawson, R.A. (1997). Your AIDS IQ: Can counselors cope with high risk populations? *Professional Counselor* 12(2), 43-45.
4. Rawson, R.A., McCann, M.J., Huber, A., **Shoptaw, S.** (1997). Contingency management and relapse prevention as stimulant abuse treatment interventions. In: S.T. Higgins & K. Silverman (Eds.), *Motivating behavior change among illicit drug abusers: contemporary research on contingency management interventions*. Washington, D.C.: American Psychological Association Press.
5. **Shoptaw, S.**, Reback, C.J., Freese, T.E., Rawson, R.A. (1998). *Behavioral interventions for methamphetamine abusing gay and bisexual men: A treatment manual combining relapse prevention and HIV risk-reduction interventions*. Hollywood, CA: Friends Health Center.
6. Ling, W., **Shoptaw, S.** (1998). *Methamphetamine research initiative*. California Society of Addiction Medicine News (Spring), 6.
7. Scott, R.L., **Shoptaw, S.** (1999). *An ethnographic study of the relationships between crack use, sexuality, and engaging in HIV risk behaviors among persons of African descent*. City of Los Angeles, AIDS Coordinators Office.
8. **Shoptaw, S.**, Dow, S., Frosch, D.L., Ling, W., Madsen, D.C., Jarvik, M.E. (1999). Reducing cigarette smoking in methadone maintenance patients. In S.T. Higgins & K. Silverman, (Eds.), *Motivation behavior change among illicit-drug abusers: Contemporary research on contingency-management interventions*. Washington, D.C.: American Psychological Association Press, 243-264.
9. Mayors AIDS Leadership Council, **Shoptaw, S.** (December 2003). *HIV and AIDS in Los Angeles: 21st century challenges and approaches*. A Report to the Mayor and City Council of Los Angeles.
10. Szekeres, G., Coates, T.J., Frost, S.L., Leibowitz, A., **Shoptaw, S.** (October 2004). *Anticipating the efficacy of HIV pre-exposure prophylaxis (PrEP) and the needs of at-risk Californians*. Monograph prepared for the California State Office on AIDS.
11. **Shoptaw, S.**, Reback C., Peck, J., Larkins, S., Freese, T., Rawson, R., (2005). *Getting off: A behavioral*

*treatment intervention for gay and bisexual male methamphetamine users.*

[http://www.uclaisap.org/assets/documents/Shoptawetal\\_2005\\_tx%20manual.pdf](http://www.uclaisap.org/assets/documents/Shoptawetal_2005_tx%20manual.pdf)

12. **Shoptaw, S.**, (2007) Chapter 20: Methamphetamine use & men who have sex with men. *Methamphetamine Treatment: A Practitioner's Reference 2007* (pp. 69-72). California Department of Alcohol & Drug Programs and University of California, Los Angeles Integrated Substance Abuse Programs. <http://www.adpa.ca.gov>.
13. **Shoptaw, Steven J.** (2009). Chapter 39: Sexual Addiction in Ries, R., Fiellin, D., Miller, S., Saitz, R. (Eds.), *Principles of Addiction Medicine. Fourth Edition*. Philadelphia, PA: Lippincott Williams & Wilkins.
14. Roll, J., Rawson, R., Ling, W., and **Shoptaw, S.** (Eds). (2009). Chapter 7 Methamphetamine addiction: From basic science to treatment. New York, NY: The Guilford Press.
15. Roll, J.R., Ling, W., Rawson, R.A., **Shoptaw, S.**, (Eds). (2009). Chapter 12: Psychosocial and behavioral treatment of methamphetamine dependence. *Methamphetamine*. New York, NY: The Guilford Press.
16. **Shoptaw, Steven J.** Chapter 30 Sexual addiction in Cavacuiti (Ed). (2011). *Principles of Addiction Medicine: The Essentials*. Philadelphia, PA: Lippincott Williams & Wilkins.
17. **Shoptaw, S.**, Kuo, I. (2011). Treatment as prevention for substance users and MSM. *Conference proceedings from substance use, mental health, and HIV: Integrating treatment as prevention*. Atlanta, Georgia.
18. **Shoptaw, S.**, Kao, U., Ling, K. et al. (2012). UNODC technical guide for HIV prevention, treatment and care for stimulant users. *Monograph for United Nations Office on Drugs and Crime*. Vienna, Austria.
19. Brensilver, M., Johnson, V., Grotheer, A., Bholat, M., Heinzerling, K., **Shoptaw, S.** (2012). Chapter 20: Pharmacotherapy of amphetamine-type stimulants. In S. Allsop & N. Lee (Eds.), *Perspectives on amphetamine-type stimulants*. Melbourne: IP Communications. August, 2012. 245 x 170mm. 464 pages.
20. Brensilver, M., **Shoptaw, S.** (2013). Pharmacotherapy of Cocaine Dependence. In P. Miller (Ed.), *Interventions for Addiction: Comprehensive Addictive Behaviors and Disorders*. (439–448). San Diego, CA: Elsevier, Inc.
21. Ray, LA, Roche, DJO, Heinzerling K, **Shoptaw S.** Chapter 12—Opportunities for the Development of Neuroimmune Therapies in Addiction. In C. Cui, D. Shurtleff, and R. Adron Harris (Eds.), *International Review of Neurobiology*. (381-401). Austin, TX: Elsevier, Inc.
22. Hall, TM, Reback, CJ, **Shoptaw, S.** (2015). Chapter 10—Clinical Management of Substance Use and Substance Use Disorders Among LGBT Individuals. In K. Mayer, H. Goldhammer, and H.J. Makadon (Eds.), *Fenway Guide to LGBT Health, Second Edition*. Philadelphia, PA: American College of Physicians.
23. **Shoptaw, S.** HIV Positive Gay Men, MSM, and Substance Use: Perspectives on HIV Prevention. In Wilton L, (Ed.). *Understanding Prevention for HIV Positive Gay Men: Innovative Approaches in Addressing the AIDS Epidemic*. Springer; 2017 Oct 27.
24. Hall, TM, Schriger, Simone H, & **Shoptaw, S** (2019). Chapter 46: Problematic Sexual Behaviors and "Sexual Addiction". In Herron, A & Brennan, TK (Eds.). *The ASAM Essentials of Addiction Medicine*.

Lippincott Williams & Wilkins; 3rd. Ed. 19 March 2019.

25. Albanese, T, **Shoptaw, S**, Cermak, T., & Montero, Y. In Ling, W, Stephenson, D, & Vasti, E (Eds). *California Department of Health Care Services: Guidelines for Physicians Working in California Opioid Treatment Programs*. California Society of Addiction Medicine. 21 April 2019.

## **CHAPTERS (IN PRESS)**

1. Le Mihn, G, Shoptaw, S. Chapter 9 – Psychoactive Drug Use. In Detels (Ed). *Oxford Textbook of Global Public Health*.

## **LETTERS TO THE EDITOR**

1. Miller WC, Hoffman IF, Latkin CA, Strathdee SA, **Shoptaw S**. Commentary: HIV antiretroviral prophylaxis for injecting drug users. *Lancet*. 2013 Sep 7; 382(9895):853. PMC not applicable.
2. **Shoptaw, S**. Commentary on Gowin et. al (2014): Brain is behavior—methamphetamine dependence and recovery. *Addiction*. Jan 2014. 109:248-249. PMC not applicable.
3. **Shoptaw, S**. Commentary on Konstenius et al: On Medication Development for Stimulant Addiction. *Addiction*. 2014 Mar;109(3):450-1. PMC not applicable.
4. **Shoptaw S**. A few words on ‘Which medications are suitable for agonist drug maintenance?’ *Addiction*. 2016 May;111(5):778-9. PMC in process.
5. Harawa, N.T., Holloway, I.W., Leibowitz, A., Weiss, R., Gildner, J., Landovitz, R.J., Perez, M.J., Kulkarni, S., Rotheram-Borus, M.J. and **Shoptaw, S.**, 2017. Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition. *AIDS*, 31(5), pp.739-740. PMID: PMC5580999.

## **REVIEWS**

1. Ding, Y., He, N., **Shoptaw, S.**, Gao, M., Detels, R. Severity of drug dependence and perceived need for treatment among a sample of adult club users in Shanghai, China. *Soc Psychiatry Psychiatr Epidemiol*. 2013 May 29. (Epub ahead of print). PMID: PMC3797173.

## **EDITORIALS**

None

## **OTHER**

1. Szekeres, G., Coates, T.J., Frost, S., Leibowitz, A., **Shoptaw, S**. *Anticipating the Efficacy of HIV Pre-Exposure Prophylaxis (PrEP) and the Needs of At-Risk Californians*. Center for HIV Prevention and Treatment Services Report. November 2004.
2. **Shoptaw, S**. PrEP: One Essential Tool in the HIV Prevention Toolkit. *Psychology Benefits Society: A*

Blog from the APA Public Interest Doctorate. American Psychological Association. June 24, 2016.

<https://psychologybenefits.org/2016/06/24/prep-one-essential-tool-in-the-hiv-prevention-toolkit/>

## **PAPERS IN PREPARATION (RESEARCH COMPLETED)**

1. Forthcoming

## **MEDIA / EXPERT COMMENTARY**

1. Sheff, D. *Viewpoint: We Need to Rethink Rehab*. TIME. April 3, 2013. Web Article.
2. Unknown. *An opioid epidemic may be looming in Mexico – and the US may be partly responsible*. ScienceDaily. November 29, 2018. Web Article.
3. Karlamangla, S. *A dangerous opioid is killing people in California. It's starting to show up in cocaine and meth*. Los Angeles Times. May 15, 2018. Newspaper Article.
4. Vestal, C. *So far, the deadly fentanyl epidemic hasn't hit California. Here's why*. The Washington Post. February 4, 2019. Web Article.
5. Dembosky, A. *Meth Mania: From Biker Gangs to the Psych Ward, How Speed Came of Age in California*. KQED News – The California Report. April 5, 2019. Radio Segment.
6. Halverstadt, L. *It's Been a Rough Road for Program to Get Addicted Offers Off the Street*. Voices of San Diego. April 18, 2019. Newspaper Article.
7. Halverstadt, L. *San Diego's Effort to Reduce Prison Overcrowding is Hitting Some Snags*. Pacific Standard Magazine. April 24, 2019. Magazine Article.
8. Daly, M. *The Truth About Drug Dealers Lacing Cocaine with Fentanyl*. Vice. April 5, 2019. Web Article.
9. Dembosky, A. *As Meth Use Surges, First Responders Struggle To Help Those In Crisis*. Health Shots – NPR Morning Edition. May 1, 2019. Radio Segment.
10. Dembosky, A. *Meth Vs. Opioids: America Has Two Drug Epidemics, But Focuses On One*. California Healthline. May 8, 2019. Web Article.
11. Dembosky, A. & Conley, A. *Meth Vs. Opioids: America Has Two Drug Epidemics, But Focuses On One*. California Healthline. Omaha World-Herald May 17, 2019. Newspaper Article.
12. Carrero, M. Commentary on “A Regional Response to End the HIV Epidemic in California” Regional Meeting Organized by the Center for HIV Identification, Prevention, and Treatment Services. *KNX Morning News with Dick Helton and Vicky Moore*. January 24, 2020. Radio Spot – KNX 1070.
13. Lopez, G. *The Rise in Meth and Cocaine Overdoses, Explained*. Vox. January 30, 2020. Web Article.
14. Goldstein, D. *Goldstein Investigates: 9 USC Students Die In Single Semester, 3 From Accidental Fentanyl Overdoses*. CBS Los Angeles. February 20, 2020. Television Segment. CBS2/KCAL9.



15. Wang, K. *Drug overdoses claim lives of four USC students within three weeks last semester*. USC Annenberg Media. February 24, 2020. Newspaper Article.
16. Ocamb, K. *Meth epidemic getting worse; researchers, community respond*. Los Angeles Blade. July 23, 2020. Web Article.